Endometrial Neoplasms: Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.Topotecan: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.Arctium: A plant genus of the family ASTERACEAE. Arctiin (LIGNANS) is in the seed.TOR Serine-Threonine Kinases: A serine threonine kinase that controls a wide range of growth-related cellular processes. The protein is referred to as the target of RAPAMYCIN due to the discovery that SIROLIMUS (commonly known as rapamycin) forms an inhibitory complex with TACROLIMUS BINDING PROTEIN 1A that blocks the action of its enzymatic activity.Cell Line, Tumor: A cell line derived from cultured tumor cells.Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.Antineoplastic Agents: Substances that inhibit or prevent the proliferation of NEOPLASMS.Radioisotope Teletherapy: A type of high-energy radiotherapy using a beam of gamma-radiation produced by a radioisotope source encapsulated within a teletherapy unit.Brachytherapy: A collective term for interstitial, intracavity, and surface radiotherapy. It uses small sealed or partly-sealed sources that may be placed on or near the body surface or within a natural body cavity or implanted directly into the tissues.Iridium Radioisotopes: Unstable isotopes of iridium that decay or disintegrate emitting radiation. Ir atoms with atomic weights 182-190, 192, and 194-198 are radioactive iridium isotopes.Radiotherapy Dosage: The total amount of radiation absorbed by tissues as a result of radiotherapy.Radiotherapy, Adjuvant: Radiotherapy given to augment some other form of treatment such as surgery or chemotherapy. Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.Neoplasm Recurrence, Local: The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.Wnt Proteins: Wnt proteins are a large family of secreted glycoproteins that play essential roles in EMBRYONIC AND FETAL DEVELOPMENT, and tissue maintenance. They bind to FRIZZLED RECEPTORS and act as PARACRINE PROTEIN FACTORS to initiate a variety of SIGNAL TRANSDUCTION PATHWAYS. The canonical Wnt signaling pathway stabilizes the transcriptional coactivator BETA CATENIN.Endometrium: The mucous membrane lining of the uterine cavity that is hormonally responsive during the MENSTRUAL CYCLE and PREGNANCY. The endometrium undergoes cyclic changes that characterize MENSTRUATION. After successful FERTILIZATION, it serves to sustain the developing embryo.BrazilTissue Banks: Centers for acquiring, characterizing, and storing organs or tissue for future use.Wnt Signaling Pathway: A complex signaling pathway whose name is derived from the DROSOPHILA Wg gene, which when mutated results in the wingless phenotype, and the vertebrate INT gene, which is located near integration sites of MOUSE MAMMARY TUMOR VIRUS. The signaling pathway is initiated by the binding of WNT PROTEINS to cells surface WNT RECEPTORS which interact with the AXIN SIGNALING COMPLEX and an array of second messengers that influence the actions of BETA CATENIN.Wnt3 Protein: A Wnt protein subtype that plays a role in cell-cell signaling during EMBRYONIC DEVELOPMENT and the morphogenesis of the developing NEURAL TUBE. Defects in Wnt3 protein are associated with autosomal recessive tetra-AMELIA in humans.Carcinoma, Endometrioid: An adenocarcinoma characterized by the presence of cells resembling the glandular cells of the ENDOMETRIUM. It is a common histological type of ovarian CARCINOMA and ENDOMETRIAL CARCINOMA. There is a high frequency of co-occurrence of this form of adenocarcinoma in both tissues.Prospective Studies: Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.Postmenopause: The physiological period following the MENOPAUSE, the permanent cessation of the menstrual life.Cohort Studies: Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.Risk Factors: An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.Clinical Trials, Phase II as Topic: Works about studies that are usually controlled to assess the effectiveness and dosage (if appropriate) of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques. These studies are performed on several hundred volunteers, including a limited number of patients with the target disease or disorder, and last about two years. This concept includes phase II studies conducted in both the U.S. and in other countries.Estrogen Replacement Therapy: The use of hormonal agents with estrogen-like activity in postmenopausal or other estrogen-deficient women to alleviate effects of hormone deficiency, such as vasomotor symptoms, DYSPAREUNIA, and progressive development of OSTEOPOROSIS. This may also include the use of progestational agents in combination therapy.Hormone Replacement Therapy: Therapeutic use of hormones to alleviate the effects of hormone deficiency.Renal Replacement Therapy: Procedures which temporarily or permanently remedy insufficient cleansing of body fluids by the kidneys.Enzyme Replacement Therapy: Therapeutic replacement or supplementation of defective or missing enzymes to alleviate the effects of enzyme deficiency (e.g., GLUCOSYLCERAMIDASE replacement for GAUCHER DISEASE).Internet: A loose confederation of computer communication networks around the world. The networks that make up the Internet are connected through several backbone networks. The Internet grew out of the US Government ARPAnet project and was designed to facilitate information exchange.Software: Sequential operating programs and data which instruct the functioning of a digital computer.User-Computer Interface: The portion of an interactive computer program that issues messages to and receives commands from a user.Neoplasm Staging: Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.Prognosis: A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.Follow-Up Studies: Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.Breast Neoplasms: Tumors or cancer of the human BREAST.Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.Hysteroscopy: Endoscopic examination, therapy or surgery of the interior of the uterus.Uterine Hemorrhage: Bleeding from blood vessels in the UTERUS, sometimes manifested as vaginal bleeding.Uterine Diseases: Pathological processes involving any part of the UTERUS.Curettage: A scraping, usually of the interior of a cavity or tract, for removal of new growth or other abnormal tissue, or to obtain material for tissue diagnosis. It is performed with a curet (curette), a spoon-shaped instrument designed for that purpose. (From Stedman, 25th ed & Dorland, 27th ed)Biopsy: Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.Uterine Neoplasms: Tumors or cancer of the UTERUS.Genital Neoplasms, Male: Tumor or cancer of the MALE GENITALIA.Practice Guidelines as Topic: Directions or principles presenting current or future rules of policy for assisting health care practitioners in patient care decisions regarding diagnosis, therapy, or related clinical circumstances. The guidelines may be developed by government agencies at any level, institutions, professional societies, governing boards, or by the convening of expert panels. The guidelines form a basis for the evaluation of all aspects of health care and delivery.Carcinoma: A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)Guidelines as Topic: A systematic statement of policy rules or principles. Guidelines may be developed by government agencies at any level, institutions, professional societies, governing boards, or by convening expert panels. The text may be cursive or in outline form but is generally a comprehensive guide to problems and approaches in any field of activity. For guidelines in the field of health care and clinical medicine, PRACTICE GUIDELINES AS TOPIC is available.
Analysis of TSG101 tumour susceptibility gene transcripts in cervical and endometrial cancers. (1/2234)Carcinoma of the uterine cervix is a common malignancy among women that has been found to show loss of heterozygosity in the chromosome 11p. Recent studies have localized the TSG101 gene in this region, and also demonstrated a high frequency of abnormalities of this gene in human breast cancer. To determine the role of the TSG101 gene in the carcinogenesis of cervical and uterine carcinoma, 19 cases of cervical carcinoma and five cases of endometrial carcinoma, as well as nearby non-cancerous tissue from the same patients, and 16 blood samples from healthy persons as normal control were analysed by Southern blot analysis of genomic DNA, reverse transcription of the TSG101 mRNA followed by PCR amplification and sequencing of the products. We found that abnormal transcripts of the TSG101 gene were common both in cancerous or non-cancerous tissues of the uterus and cervix and in normal peripheral mononuclear cells. There was no genomic deletion or rearrangement in spite of the presence of abnormal transcripts, and no definite relationship between the abnormal transcripts and HPV infection was found. Although the frequency of abnormal transcripts was higher in cancerous than in non-cancerous tissue, normal peripheral mononuclear cells also had abnormal transcripts. Given these findings, the role of the TSG101 gene as a tumour-suppressor gene should be re-evaluated. Because some aberrant transcripts could be found at the first PCR reaction, we suggest that the aberrant transcripts might be the result of imperfect minor splicesome products. (+info)
Low levels of cathepsin D are associated with a poor prognosis in endometrial cancer. (2/2234)Total cytosolic cathepsin D (Cat D) levels were estimated by an immunoradiometric assay in a series of 156 consecutive patients with surgical stages I-III primary endometrial adenocarcinoma. Simultaneously, the tissue content of both oestrogen (ER) and progesterone (PR) receptors, and p185HER-2/neu, DNA content (ploidy), and the fraction of S-phase cells (S-phase) were also estimated. Tumoral Cat D content ranged from 0 to 243 pmol mg(-1) protein (median 44 pmol mg(-1) protein) and was not associated with any of the established clinicopathological and biological prognostic variables, with the exception of a weak positive correlation with the tumoral p185HER-2/neu levels. Univariable analysis performed on a subset of 97 patients, followed for a minimum of 2 years or until death, showed that patient age at diagnosis, high histological grade, advanced surgical stage, vascular invasion, positive peritoneal cytology, low levels of Cat D, negative ER and PR status, aneuploidy, and high S-phase were predictive of the presence of persistent or recurrent disease. However, multivariable analysis revealed that only histological grade, surgical stage, Cat D and PR were significantly associated with the patient's outcome. From these findings, we conclude that Cat D is an independent prognostic factor in endometrial adenocarcinoma, its low levels being associated with a worse clinical outcome. (+info)
Cancer risk in close relatives of women with early-onset breast cancer--a population-based incidence study. (3/2234)Inherited susceptibility to breast cancer is associated with an early onset and bilateral disease. The extent of familial risks has not, however, been fully assessed in population-based incidence studies. The purpose of the study was to quantify the risks for cancers of the breast, ovary and other sites of close relatives of women in whom breast cancer was diagnosed at an early age. Records collected between 1943 and 1990 at the Danish Cancer Registry were searched, and 2860 women were found in whom breast cancer was diagnosed before age 40. Population registers and parish records were used to identify 14 973 parents, siblings and offspring of these women. Cancer occurrence through to 31 December 1993 was determined within the Cancer Registry's files and compared with national incidence rates. Women with early-onset breast cancer were at a nearly fourfold increased risk of developing a new cancer later in life (268 observed vs. 68.9 expected). The excess risk was most evident for second cancer of the breast (181 vs. 24.5) and for ovarian cancer (20 vs. 3.3). For mothers and sisters, risks for cancers of the breast and ovary were significantly increased by two- to threefold. Bilateral breast cancer and breast-ovarian cancer were very strong predictors of familial risks, with one in four female relatives predicted to develop breast and/or ovarian cancer by age 75. Mothers had a slightly increased risk of colon cancer, but not endometrial cancer. The risk for breast cancer was also increased among fathers (standardized incidence ratio 2.5; 95% CI 0.5-7.4) and especially brothers (29; 7.7-74), although based on small numbers. The risk for prostatic cancer was unremarkable. In this large population-based survey, the first-degree relatives of women who developed breast cancer before age 40 were prone to ovarian cancer as well as male and female breast cancer, but not other tumours that may share susceptibility genes with breast cancer. (+info)
Molecular mechanisms of proliferation in endometrial tumour cells. (4/2234)The human endometrium normally undergoes a cyclic proliferation process followed by differentiation under the influence of ovarian steroids and locally produced growth and differentiation factors. Understanding of the molecular mechanisms involved in controlling these processes is of great interest, since imbalances between proliferation- and differentiation-promoting signals can have pathophysiological consequences ranging from infertility to endometrial hyperplasia and tumour formation. The present work reviews aspects of the role played by oncogenes and ovarian steroid receptors in modulating proliferation of endometrial tumour cells. The expression pattern and possible roles of protein kinase C (PKC) subunits are discussed in the context of response-specificity of endometrial tumour cells to tumour-promoting agents such as 12-O-tetradecanoyl-phorbol acetate (TPA) and possible implications for anti-tumour therapy. (+info)
A common MSH2 mutation in English and North American HNPCC families: origin, phenotypic expression, and sex specific differences in colorectal cancer. (5/2234)The frequency, origin, and phenotypic expression of a germline MSH2 gene mutation previously identified in seven kindreds with hereditary non-polyposis cancer syndrome (HNPCC) was investigated. The mutation (A-->T at nt943+3) disrupts the 3' splice site of exon 5 leading to the deletion of this exon from MSH2 mRNA and represents the only frequent MSH2 mutation so far reported. Although this mutation was initially detected in four of 33 colorectal cancer families analysed from eastern England, more extensive analysis has reduced the frequency to four of 52 (8%) English HNPCC kindreds analysed. In contrast, the MSH2 mutation was identified in 10 of 20 (50%) separately identified colorectal families from Newfoundland. To investigate the origin of this mutation in colorectal cancer families from England (n=4), Newfoundland (n=10), and the United States (n=3), haplotype analysis using microsatellite markers linked to MSH2 was performed. Within the English and US families there was little evidence for a recent common origin of the MSH2 splice site mutation in most families. In contrast, a common haplotype was identified at the two flanking markers (CA5 and D2S288) in eight of the Newfoundland families. These findings suggested a founder effect within Newfoundland similar to that reported by others for two MLH1 mutations in Finnish HNPCC families. We calculated age related risks of all, colorectal, endometrial, and ovarian cancers in nt943+3 A-->T MSH2 mutation carriers (n=76) for all patients and for men and women separately. For both sexes combined, the penetrances at age 60 years for all cancers and for colorectal cancer were 0.86 and 0.57, respectively. The risk of colorectal cancer was significantly higher (p<0.01) in males than females (0.63 v 0.30 and 0.84 v 0.44 at ages 50 and 60 years, respectively). For females there was a high risk of endometrial cancer (0.5 at age 60 years) and premenopausal ovarian cancer (0.2 at 50 years). These intersex differences in colorectal cancer risks have implications for screening programmes and for attempts to identify colorectal cancer susceptibility modifiers. (+info)
Gonadotropin-releasing hormone analogue conjugates with strong selective antitumor activity. (6/2234)Conjugation of gonadotropin-releasing hormone (GnRH) analogues GnRH-III, MI-1544, and MI-1892 through lysyl side chains and a tetrapeptide spacer, Gly-Phe-Leu-Gly (X) to a copolymer, poly(N-vinylpyrrolidone-co-maleic acid) (P) caused increased antiproliferative activity toward MCF-7 and MDA-MB-231 breast, PC3 and LNCaP prostate, and Ishikawa endometrial cancer cell lines in culture and against tumor development by xenografts of the breast cancer cells in immunodeficient mice. MCF-7 cells treated with P-X-1544 and P-X-1892 displayed characteristic signs of apoptosis, including vacuoles in the cytoplasm, rounding up, apoptotic bodies, bleb formation, and DNA fragmentation. Conjugates, but not free peptides, inhibited cdc25 phosphatase and caused accumulation of Ishikawa and PC3 cells in the G2/M phase of the cell cycle after 24 h at lower doses and in the G1 and G2 phases after 48 h. Since P-X-peptides appear to be internalized, the increased cytotoxicity of the conjugates is attributed to protection of peptides from proteolysis, enhanced interaction of the peptides with the GnRH receptors, and/or internalization of P-X-peptide receptor complexes so that P can exert toxic effects inside, possibly by inhibiting enzymes involved in the cell cycle. The additional specificity of P-X-peptides compared with free peptides for direct antiproliferative effects on the cancer cells but not for interactions in the pituitary indicates the therapeutic potential of the conjugates. (+info)
MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. (7/2234)Defective DNA mismatch repair in human tumors leads to genome-wide instability of microsatellite repeats and a molecular phenotype referred to as microsatellite instability (MSI). MSI has been reported in a variety of cancers and is a consistent feature of tumors from patients with hereditary non-polyposis colorectal cancer. Approximately 20% of cancers of the uterine endometrium, the fifth most common cancer of women world-wide, exhibit MSI. Although the frequency of MSI is higher in endometrial cancers than in any other common malignancy, the genetic basis of MSI in these tumors has remained elusive. We investigated the role that methylation of the MLH1 DNA mismatch repair gene plays in the genesis of MSI in a large series of sporadic endometrial cancers. The MLH1 promoter was methylated in 41 of 53 (77%) MSI-positive cancers investigated. In MSI-negative tumors on the other hand, there was evidence for limited methylation in only one of 11 tumors studied. Immunohistochemical investigation of a subset of the tumors revealed that methylation of the MLH1 promoter in MSI-positive tumors was associated with loss of MLH1 expression. Immunohistochemistry proved that two MSI-positive tumors lacking MLH1 methylation failed to express the MSH2 mismatch repair gene. Both of these cancers came from women who had family and medical histories suggestive of inherited cancer susceptibility. These observations suggest that epigenetic changes in the MLH1 locus account for MSI in most cases of sporadic endometrial cancers and provide additional evidence that the MSH2 gene may contribute substantially to inherited forms of endometrial cancer. (+info)
Mismatch repair gene defects contribute to the genetic basis of double primary cancers of the colorectum and endometrium. (8/2234)Hereditary non-polyposis colorectal cancer (HNPCC) is a dominantly inherited cancer syndrome caused by germline defects of mismatch repair (MMR) genes. Endometrial cancer is the most common extracolonic neoplasm in HNPCC and is the primary clinical manifestation of the syndrome in some families. The cumulative incidence of endometrial cancer among HNPCC mutation carriers is high, estimated to be from 22 to 43%. We hypothesized that women with double primary cancers of the colorectum and endometrium are likely to be members of HNPCC families. In order to determine how frequently HNPCC manifests in the context of double primary cancers, we examined alterations of two MMR genes, hMSH2 and hMLH1, in 40 unrelated women affected with double primary cancers. These cases were identified using hospital-based and population-based cancer registries in Ontario, Canada. MMR gene mutations were screened by single-strand conformation polymorphism analysis and confirmed by direct sequencing. Eighteen percent (seven of 40) were found to harbor mutations of one of the two MMR genes. Analysis of colorectal and/or endometrial tumors of mutation-negative probands found microsatellite instability in seven of 20 cases. Six of seven mutation-positive probands had strong family histories suggestive of HNPCC. First degree relatives of mutation-positive probands had a very high relative risk (RR) of colorectal cancer (RR = 8.1, CI 3. 5-15.9) and endometrial cancer (RR = 23.8, CI 6.4-61.0). The relative risk of mutation-negative cases was 2.8 (CI 1.7-4.5) for colorectal cancer and 5.4 (CI 2.0-11.7) for endometrial cancer. We recommend that all double primary patients with cancers at these sites should have a genetic evaluation, including molecular analysis for HNPCC where appropriate. (+info)
Laparoscopy versus laparotomy for the management of early stage endometrial cancer.<...
TY - JOUR. T1 - Laparoscopy versus laparotomy for the management of early stage endometrial cancer.. AU - Galaal, Khadra. AU - Bryant, Andrew. AU - Fisher, Ann D.. AU - Al-Khaduri, Maha. AU - Kew, Fiona. AU - Lopes, Alberto D.. PY - 2012. Y1 - 2012. N2 - Traditionally, surgery for endometrial cancer (hysterectomy with removal of both fallopian tubes and ovaries) is performed through laparotomy. It has been suggested that the laparoscopic approach is associated with a reduction in operative morbidity. Over the last 10 to 15 years there has been a steady increase of laparoscopy for endometrial cancer. This review investigates the evidence of benefits and harms of laparoscopic surgery compared with laparotomy for presumed early stage endometrial cancer. To compare the overall survival (OS) and disease-free survival (DFS) for laparoscopic surgery versus laparotomy in women with presumed early stage endometrial cancer. We searched the Cochrane Gynaecological Cancer Group Trials Register, Cochrane ...
MicroRNA-340 Inhibits Tumor Cell Proliferation and Induces Apoptosis in Endometrial Carcinoma Cell Line RL 95-2 - Order...
Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial Cancers -...
Endometrial cancer is the most common malignancy of the female reproductive tract. The majority of patients with endometrial cancer are diagnosed at an early stage and cured with surgery with or without adjuvant radiotherapy. However, a significant number of patients present with metastatic disease outside of the pelvis or develop recurrent disease after primary therapy.. mTOR inhibitors have been shown to be promising agents in reducing tumor growth in vitro and in vivo, in several solid cancers. Inhibitors of mTOR are primarily cytostatic in cancer cells; combination therapy with cytotoxic chemotherapeutics and other biologic agents may prove to be the most advantageous use of these drugs. mTOR inhibition with a rapamycin analogue demonstrated in vitro antiproliferative activity on endometrial AN3 CA and HEC-1-A tumor cells, and this inhibition of proliferation was found to be concentration dependent. Topotecan is an active agent in the treatment of advanced and recurrent endometrial cancers. ...
Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic...
We evaluated the efficacy and safety of the aromatase inhibitor exemestane in patients with advanced, persistent or recurrent endometrial carcinoma. We performed an open-label one-arm, two-stage, phase II study of 25 mg of oral exemestane in 51 patients with advanced (FIGO stage III-IV) or relapsed endometrioid endometrial cancer. Patients were stratified into subsets of estrogen receptor (ER) positive and ER negative patients. Recruitment to the ER negative group was stopped prematurely after 12 patients due to slow accrual. In the ER positive patients, we observed an overall response rate of 10%, and a lack of progression after 6 months in 35% of the patients. No responses were registered in the ER negative patients, and all had progressive disease within 6 months. For the total group of patients, the median progression free survival (PFS) was 3.1 months (95% CI: 2.0-4.1). In the ER positive patients the median PFS was 3.8 months (95% CI: 0.7-6.9) and in the ER negative patients it was 2.6 months (95%
Women Health: Endometrial Cancer In Folate Perspective
One-carbon metabolism dietary factors, including levels of folate, choline, methionine, vitamin B2, vitamin B6 or vitamin B12, do not effect the endometrial incidence(4). But in Type I and II endometrial cancer study, intake of use of supplements containing folate and vitamins B2, B6, and B12 was associated with an increased risk of type II endometrial cancer.(5). The Folate (FOL) mediated poly-lactide-co-glycolide-polyethylene glycol nanoparticles (FOL-PEG-PLGA NPs) bearing paclitaxel (PTX), was found to be effective in indcution of cytotoxicity against HEC-1A cancer cells in vitro and in vivo, through possibly induced apoptosis(6). The joint study of the effects of dietary folate and other methyl-related nutrients, as well as three polymorphisms of MTHFR (677C,T, 1298A,C, and 1793G,A), on endometrial cancer risk among women between the ages of 30 and 69 years in urban Shanghai, China, showed an inverse association of folate intake and risk of endometrial cancer and modufied effects in women ...
Follow-up of Endometrial Cancer Patients
Endometrial Cancer and Copy Number Variation
Endometrial cancer is the most common gynaecological cancer in New Zealand and the incidence is increasing as the population ages. Genetic predictors of endometrial cancer risk that allow early detection of the disease are important for prevention and improved management strategies. Mutations in the mismatch repair (MMR) genes MLH1, MSH2, MSH6, PMS1 and PMS2 are known to confer increased risk in a proportion of endometrial cancer cases, and the mutation spectrum includes copy number variants (CNVs). There are several other genes encoding proteins that act in the MMR pathways, but to date the evidence for their involvement in endometrial cancer predisposition is limited. This study aims to 1) To identify genes in the MMR pathway that are overlapped by CNVs in endometrial cancer cases, 2) To compare the CNV frequency of common and rare CNVs between endometrial cancer cases and controls, 3) To identify regions in the genome that are associated with endometrial cancer risk, and 4) To identify ...
Cytostatic effects of 3,3′-diindolylmethane in human endometrial cancer cells result from an estrogen receptor-mediated...
3,3′-Diindolylmethane (DIM), a major in vivo product of indole-3-carbinol (I3C), is a promising anticancer agent derived from vegetables of the Brassica genus including broccoli, Brussels sprouts and cabbage. We report here that DIM has a potent cytostatic effect in cultured human Ishikawa endometrial cancer cells. A combination of northern blot and quantitative PCR analyses revealed that DIM induced the level of TGF-α transcripts by ~4-fold within 24 h of indole treatment. DIM also induced a 4-fold increase in the activity of the estrogen response marker, alkaline phosphatase (AP). Co-treatment of cells with the estrogen receptor (ER) antagonist ICI, or with the inhibitor of PKA-mediated activation of the ER, H89, ablated the DIM induction of both TGF-α expression and AP activity. Furthermore, DIM increased the maximum stimulatory effect of estrogen on TGF-α expression. Co-treatment with the protein synthesis inhibitor, cycloheximide, abolished the inductive effects of DIM, indicating ...
Microscopic Omental Metastasis in Clinical Stage I Endometrial Cancer: A Meta-analysis | Springer for Research & Development
The overwhelming majority of the patients without endometrial cancer (99 of 109) revealed no or fewer than three genes methylated, whereas all of the 15 endometrial cancer patients had three or more genes methylated in their vaginal secretion (P , 0.001, χ2 test; Fig. 3A). Histological examination of the 10 patients in the no endometrial cancer group with three or more genes methylated revealed invasive cervical cancer (four cases), CIN III (one case), endometrium polyp (four cases), and fibroids (one case). Samples were collected after primary surgery (curettage, punch biopsy of the cervix, or hysteroscopic operation) and before secondary surgery (hysterectomy) in 16 of 124 patients: 9 of 16 patients had endometrial cancer, 3 of 16 patients had CIN III, and 4 of 16 patients had benign disease of the endometrium. All nine endometrial cancer patients had a diagnosis of residual cancer at the time of secondary surgery. All nine endometrial cancer patients had three or more genes methylated, the ...
Update on prognostic markers for endometrial cancer<...
TY - JOUR. T1 - Update on prognostic markers for endometrial cancer. AU - Binder, Pratibha S.. AU - Mutch, David G.. PY - 2014/5. Y1 - 2014/5. N2 - Endometrial cancer is the most common gynecologic cancer in the USA and the second most common worldwide after cervical cancer. While common symptomatology of endometrial cancer leads to early diagnosis and favorable 5-year survival in most cases, there is a subset of cancers that have a poorer prognosis. The clinical and pathologic prognostic factors for endometrial cancer are well known and instrumental in determining the need for adjuvant therapy. Recently, research has been focused on the identification of molecular changes leading to different histologic subtypes to improve classification of endometrial cancer. The identification of novel mutations and molecular profiles should enhance our ability to personalize adjuvant treatment with genome-guided targeted therapy.. AB - Endometrial cancer is the most common gynecologic cancer in the USA and ...
Development of DNA methylation biomarker for endometrial cancer detection - Taipei Medical University
Endometrial cancer (EC) is a common gynecological cancer. Endometrial cancer (EC) is a common gynecological cancer. The detection of endometrial cancers are ,80% curable in early stage, but dramatic decreasing ,30% of cures in late stage. There 1757 new cases occurred and increased 30% of incidence on 2012 in Taiwan. In addition, the incidents of EC are growing up annually in worldwide and Taiwan. However, no feasible screening method for detecting endometrial cancer. There is an urgent need of biomarkers for detecting endometrial cancer patients. The development of effective methods of detection of EC is also needed. Epigenetic alterations have been shown to occur in many types of cancer. Decades of researches have demonstrated the potential of DNA methylation as a marker for early diagnosis of cancer. The genome-side methylation studies could leads to discover novel genes for detection. We analyzed two methylomics data of endometrial cancers for discovery of novel methylation biomarker using ...
Adjuvant therapy for endometrial cancer<...
TY - JOUR. T1 - Adjuvant therapy for endometrial cancer. AU - DeLeon, Maria C.. AU - Ammakkanavar, Natraj R.. AU - Matei, Daniela. PY - 2014/1/1. Y1 - 2014/1/1. N2 - Endometrial cancer is a common gynecologic malignancy typically diagnosed at early stage and cured with surgery alone. Adjuvant therapy is tailored according to the risk of recurrence, estimated based on the International Federation of Gynecology and Obstetrics (FIGO) stage and other histological factors. The objective of this manuscript is to review the evidence guiding adjuvant therapy for early stage and locally advanced uterine cancer. For patients with early stage disease, minimizing toxicity, while preserving outstanding cure rates remains the major goal. For patients with locally advanced endometrial cancer optimal combined regimens are being defined. Risk stratification based on molecular traits is under development and may aid refine the current risk prediction model and permit personalized approaches for women with ...
Regulation of orphan receptor ERRα by estrogen and progesterone in endometrial carcinoma cell line--《Journal of Peking...
Objective:To explore the relationship between expression of ERRα mRNA and estrogen and progesterone and to elucidate the function of ERRα in endometrial carcinoma. Methods:The expression of ERRα mRNA was examined by reverse transcription polymerase chain reaction. Endometrial carcinoma cell line Ishikawa was dealt with different concentrations of 17β-estradiol(10 -10 mol/L,10 -8 mol/L and 10 -6 mol/L) for 15 min,30 min and 24 h and 17β-estradiol and ER inhibitor-ICI182780 were given concomitantly to observe the change of ERRα mRNA. Different concentrations of progesterone (10 -8 mol/L,10 -7 mol/L,10 -6 mol/L and 10 -5 mol/L)were also given to Ishikawa cell line for 24 h to observe the change of ERRα mRNA. Results:The expression level of ERRα mRNA was slightly higher than that of the control group after being stimulated for 15 min, 30 min and 24 h by 10 -10 mol/L 17β-estradiol. However the expression level of ERRα mRNA was significantly lower than that of
Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer - Results from two randomised studies
Introduction: Endometrial cancer patients with high grade tumours, deep myometrial invasion or advanced stage disease have a poor prognosis. Randomised studies have demonstrated the prevention of loco-regional relapses with radiotherapy (RT) with no effect on overall survival (OS). The possible additive effect of chemotherapy (CT) remains unclear. Two randomised clinical trials (NSGO-EC-9501/EORTC-55991 and MaNGO ILIADE-III) were undertaken to clarify if sequential combination of chemotherapy and radiotherapy improves progression-free survival (PFS) in high-risk endometrial cancer. The two studies were pooled. Methods: Patients (n = 540; 534 evaluable) with operated endometrial cancer International Federation of Obstetrics and Gynaecology (FIGO) stage I-III with no residual tumour andprognostic factors implying high-risk were randomly allocated to adjuvant radiotherapy with or without sequential chemotherapy. Results: In the NSGO/EORTC study, the combined modality treatment was associated with ...
Metastatic Endometrial Cancer (Stage 4 Cancer) - DiseaseFix
Gene expression analysis of fibroblast growth factor in a rat model of human endometrial cancer
The fibroblast growth factor receptor (FGF/FGFR) signaling has a significant role in normal organ development, like vascular and skeletal development. The dysregulation of the fibroblast growth receptor signaling occursdue to genetic modification or over expression of the receptor. This has been observed in different carcinomas [34,35].The endometrial carcinoma is the most common gynecologic malignancy in western counties and fourth most common cancer among women worldwide.Type I endometrial carcinomas constitute approximately 70 to 80% of all endometrium cancer.Itfollows estrogens related pathways in carcinogenesis. The BDII rat model is an ideal model for hormonal carcinogenesis because 90% of the female virgin spontaneously develop type I hormone independent endometrial adenocarcinomas within two years of age. Fibroblast growth factor (FGF) ligands via FGFR combined with heparan sulfate proteoglycans (HPSG) in extracellular matrix with the help of proteases and participate in the signal ...
Long term follow-up of a phase II trial of multimodal therapy given in a "sandwich" method for stage III, IV, and recurrent...
Our objective was to determine if previously reported overall survival (OS) and progression-free survival (PFS) rates are maintained long term following multimodal therapy for advanced and recurrent endometrial cancer and to assess the lymphedema rates associated with this therapy. Women with advanced-stage or recurrent endometrial cancer were recruited between 9/2004 and 6/2009 to our previously published Phase II trial. Patients received intravenous docetaxel (75 mg/m2) and carboplatin (AUC = 6) every 3 weeks for 3 cycles before and after radiation therapy. Patient outcomes were updated in July 2014. Data abstracted included presence of lymphedema, disease progression, and death. OS and PFS estimates at 5 years were calculated using Kaplan-Meier methods. Of the 41 patients enrolled, 10 (24 %) had stage IIIA and 21 (51 %) had stage IIIC disease; 32 (78 %) had endometrioid histology; and 35 (85 %) completed the protocol. With a median follow-up of 5 years, 15 of 41 patients have died. The Kaplan-Meier
EGFR isoforms and gene regulation in human endometrial cancer cells | Molecular Cancer | Full Text
Epidermal growth factor (EGF) and its receptor (EGFR) constitute a principal growth-promoting pathway in endometrial cancer cells. Pre-clinical studies were undertaken to compare the expression of EGFR isoforms and the downstream effects of activating or blocking EGFR function in Ishikawa H cells, derived from a moderately differentiated type I endometrioid adenocarcinoma, or in Hec50co cells, derived from a poorly differentiated type II adenocarcinoma with papillary serous sub-differentiation. We investigated whether EGFR mutations are present in the tyrosine kinase domain (exons 18-22) of EGFR and also whether EGFR isoforms are expressed in the Ishikawa H or Hec50co cell lines. Sequence of the EGFR tyrosine kinase domain proved to be wild type in both cell lines. While both cell lines expressed full-length EGFR (isoform A), EGFR and sEGFR (isoform D) were expressed at significantly lower levels in Hec50co cells compared to Ishikawa H cells. Analysis of gene expression following EGF vs. gefitinib
Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance | BMC Cancer | Full Text
The purpose of this study was to evaluate serum HE4 as a biomarker to detect recurrent disease during follow-up of patients with endometrial adenocarcinoma (EAC). We performed a retrospective analysis of 98 EAC patients treated at Innsbruck Medical University, between 1999 and 2009. Twenty-six patients developed recurrent disease. Median follow-up was 5 years. Serum HE4 and CA125 levels were analyzed using the ARCHITECT assay (Abbott, Wiesbaden, Germany) pre-operatively (baseline), post-operative (interval) and after histological confirmation of recurrent disease or when patients returned for clinical review with no evidence of recurrent disease (recurrence/final)). Receiver operator curves (ROC), Spearman rank correlation coefficient, chi-squared and Mann-Whitney tests were used for statistical analysis. HE4 levels decreased after initial treatment (p = 0.001) and increased again at recurrence (p = 0.002). HE4 was elevated (>70 pmol/L) in 21 of 26 (81%) and CA125 was elevated (>35 U/ml) in 12 of 26 (46
Endometrial cancer is the most common gynecologic malignancy in the United States. An estimated 47,130 women were diagnosed with uterine cancer in 2012, and an estimated 8,010 of these women will die of the disease (1). Type I endometrial cancer account for approximately 80% of cases, are classically of endometrioid histology, and are associated with obesity in up to 90% of cases. In addition, type II diabetes is associated with an increased risk for the development of endometrial cancer (2, 3).. The oral biguanide, metformin, is one of the most commonly used hypoglycemic agents in the management of type II diabetes. Epidemiological studies have demonstrated that diabetic patients being treated with metformin have a reduced cancer incidence or improved response to chemotherapy when compared with patients receiving other oral hypoglycemic agents or insulin (4-6). A meta-analysis of 5 observational studies of all cancer types found that metformin was associated with a 31% decrease in cancer risk ...
Endometrial cancer risk factors by 2 main histologic subtypes: the NIH-AARP Diet and Health Study. - Semantic Scholar
On the basis of clinical and pathologic criteria, endometrial carcinoma has been distinguished as types I (mainly endometrioid) and II (nonendometrioid). Limited data suggest that these subtypes have different risk factor profiles. The authors prospectively evaluated risk factors for types I (n = 1,312) and II (n = 138) incident endometrial carcinoma among 114,409 women in the National Institutes of Health (NIH)-AARP Diet and Health Study (1995-2006). For individual risk factors, relative risks were estimated with Cox regression by subtype, and P(heterogeneity) was assessed in case-case comparisons with type I as the referent. Stronger relations for type I versus Type II tumors were seen for menopausal hormone therapy use (relative risk (RR) of 1.18 vs. 0.84; P(heterogeneity) = 0.01) and body mass index of ≥30 vs. |30 kg/m2 (RR of 2.93 vs. 1.83; P(heterogeneity) = 0.001). Stronger relations for type II versus type I tumors were observed for being black versus white (RR of 2.18 vs. 0.66; P
Cabozantinib-S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer - Full Text View - ClinicalTrials.gov
PRIMARY OBJECTIVES:. I. Determine efficacy of single agent cabozantinib-s-malate (cabozantinib) in women previously receiving one line of chemotherapy for metastatic endometrial cancer or with progression within 12 months of completing adjuvant therapy, with co-primary endpoints of objective response rate by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and progression-free-survival at 12 weeks (PFS).. SECONDARY OBJECTIVES:. I. Correlation of clinical response with baseline molecular status of archival tumor (hepatocyte growth factor receptor [c-met] amplification & mutation status) and overall survival.. OUTLINE:. Patients receive cabozantinib-s-malate orally (PO) once daily (QD) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.. After completion of study treatment, patients are followed up every 4 weeks or every 6 months. ...
Diagnosis and Management of Endometrial Cancer - American Family Physician
Endometrial cancer is the most common gynecologic malignancy. It is the fourth most common cancer in women in the United States after breast, lung, and colorectal cancers. Risk factors are related to excessive unopposed exposure of the endometrium to estrogen, including unopposed estrogen therapy, early menarche, late menopause, tamoxifen therapy, nulliparity, infertility or failure to ovulate, and polycystic ovary syndrome. Additional risk factors are increasing age, obesity, hypertension, diabetes mellitus, and hereditary nonpolyposis colorectal cancer. The most common presentation for endometrial cancer is postmenopausal bleeding. The American Cancer Society recommends that all women older than 65 years be informed of the risks and symptoms of endometrial cancer and advised to seek evaluation if symptoms occur. There is no evidence to support endometrial cancer screening in asymptomatic women. Evaluation of a patient with suspected disease should include a pregnancy test in women of childbearing age
Mutations in PTEN Are Frequent in Endometrial Carcinoma But Rare in Other Common Gynecological Malignancies | Cancer Research
Loss of heterozygosity of chromosome 10q has been reported in approximately 40% of endometrial carcinomas. PTEN, a candidate tumor suppressor gene located at chromosome 10q23.3, was recently identified and found to be homozygously deleted or mutated in several different types of human tumors. To determine if PTEN is a target of 10q loss of heterozygosity in carcinomas of the endometrium, we examined 32 primary endometrial carcinomas for mutations in PTEN. The tumors included the two major histopathological types of endometrial carcinoma: endometrioid (n = 26; 14 microsatellite instability (MI)-positive and 12 MI-negative) and serous (n = 6). Overall, mutations were detected in 50% of the endometrial carcinomas we analyzed. Mutations were present in 12 of 14 (86%) MI-positive and 4 of 12 (33%) MI-negative endometrioid tumors. Furthermore, mutations were found in all three histological grades of MI-positive endometrioid carcinoma. All six serous endometrial carcinomas lacked detectable mutations. ...
In this study, women with the A2 allele of CYP17 were at decreased risk of endometrial cancer. Among postmenopausal women, we did not detect strong associations between CYP17 genotype and circulating steroid hormone levels. We did observe a significant interaction between CYP17 genotype and first-degree family history of endometrial and colorectal cancer, but we did not observe the endometrial cancer risk that is associated with CYP17 genotype to be substantially altered by other established hormone-related endometrial cancer risk factors.. The established risk factors for endometrial cancer are understood to act by altering chronic estrogen exposure unopposed by progesterone (3) . Likewise, the hypothesized mechanism through which genetic variation in CYP17 may influence endometrial cancer risk is by altering a womans lifetime exposure to endogenous steroid hormones. On the basis of the enzymatic steps catalyzed by CYP17, we would expect carriers of one or two A2 alleles to have elevated ...
A case-control study on endometrial cancer in relation to cigarette smoking, serum estrogen levels, and alcohol use. | Base...
OBJECTIVES : The purpose of this study was to evaluate the effect of cigarette smoking and alcohol use on the risk of endometrial cancer. The impact of smoking on serum estrone, estradiol, and androstenedione levels also was examined. STUDY DESIGN : This hospital-based case-control study included 168 women with endometrial carcinoma and 334...
Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
Progesterone receptor gene variants and risk of endometrial cancer : Carcinogenesis - oi
Prolonged excessive estrogen exposure unopposed by progesterone is widely accepted to be a risk factor for endometrial cancer development. The physiological function of progesterone is dependent upon the presence of its receptor [progesterone receptor (PGR)] and several studies have reported single nucleotide polymorphisms (SNPs) in the PGR gene to be associated with endometrial cancer risk. We sought to confirm the associations with endometrial cancer risk previously reported for four different PGR polymorphisms. A maximum of 2888 endometrial cancer cases and 4483 female control subjects from up to three studies were genotyped for four PGR polymorphisms (rs1042838, rs10895068, rs11224561 and rs471767). Logistic regression with adjustment for age, study, ethnicity and body mass index was performed to calculate odds ratios (ORs) and associated 95% confidence intervals (CIs) and P-values. Of the four SNPs investigated, only rs11224561 in the 3′ region of the PGR gene was found to be ...
Tamoxifen resistance and tamoxifen-induced endometrial proliferation are major limitations of tamoxifen therapy and chemoprevention. The present study shows that MSA inhibition of ERα signaling is not restricted to tamoxifen-sensitive MCF-7 cells. MSA antagonism of estradiol-dependent ERE2e1b-luciferase and endogenous c-myc and pS2 gene expression was shown in MCF-7-LCC2 cells, an ERα-positive, tamoxifen-resistant variant of the MCF-7 parental line and in two ERα-positive human endometrial cancer cell lines, Ishikawa and HEC1A (Figs. 1 and 2). In addition, MSA also blocked tamoxifen activation of these genes in endometrial Ishikawa and HEC1A cells (Fig. 1 and Fig. 2C-D, column 6). The major mechanism for MSA disruption of ER signaling in all ERα-positive cells lines was via rapid decrease of ERα mRNA and protein that preceded disruption of ERα-regulated gene expression (Figs. 3 and 4). MSA alone inhibited the growth of tamoxifen-sensitive, tamoxifen-resistant and endometrial-derived cells. ...
Prognostic importance of CDK4/6-specific activity as a predictive marker for recurrence in patients with endometrial cancer,...
TY - JOUR. T1 - Prognostic importance of CDK4/6-specific activity as a predictive marker for recurrence in patients with endometrial cancer, with or without adjuvant chemotherapy. AU - Ikeda, Yuji. AU - Oda, Katsutoshi. AU - Ishihara, Hideki. AU - Wada-Hiraike, Osamu. AU - Miyasaka, Aki. AU - Kashiyama, Tomoko. AU - Inaba, Kanako. AU - Fukuda, Tomohiko. AU - Sone, Kenbun. AU - Matsumoto, Yoko. AU - Arimoto, Takahide. AU - Maeda, Daichi. AU - Ikemura, Masako. AU - Fukayama, Masahi. AU - Kawana, Kei. AU - Yano, Tetsu. AU - Aoki, Daisuke. AU - Osuga, Yutaka. AU - Fujii, Tomoyuki. PY - 2015/11/17. Y1 - 2015/11/17. N2 - Background:Pathologically low-risk endometrial cancer patients do not receive postoperative treatment; however, 10-15% of these patients show recurrence with poor prognosis. We evaluated the clinical importance of cyclin-dependent kinase 4/6 (CDK4/6) activity, and its significance as a novel biomarker for the prognosis and chemo-sensitivity of endometrioid endometrial carcinoma ...
Inflamed fibroids during pregnancy - what is red degeneration of fibroid
They grow in response to excess oestrogen, or in other words oestrogen dominance, where the natural progesterone is not being balanced by the oestrogen in the body. Also, your doctor may advise that you not use tampons or have sexual intercourse during recovery. Although I have a history of fibroids - for which I was treated with a fibroid embolization type surgery which essencially killed all of my active fibroids... fibroids and pregnancy diet plan et al 14 transplanted both ER-positive and ER-negative human endometrial cancer cell lines into nude mice and evaluated the effect of both tamoxifen and 17-beta-estradiol on tumor growth.
KPNA2 is overexpressed in human and mouse endometrial cancers and promotes cellular proliferation - CaltechAUTHORS
Endometrial cancer is the most frequently occurring malignancy of the female genital tract in Western countries. Although in many cases surgically curable, about 30% of the tumours represent an aggressive and untreatable disease. In an attempt to establish a reliable prognostic marker for endometrial carcinomas disregarding their histological diversity, we investigated the expression of KPNA2, a mediator of nucleocytoplasmic transport, and other cell proliferation-associated proteins and their correlation with cancer progression. We analysed patient tissue microarrays (TMAs) assembled from 527 endometrial cancer tissue specimens and uterus samples from a Trp53 knockout mouse model of endometrial cancer. Our data show that KPNA2 expression was significantly up-regulated in human endometrial carcinomas and associated with higher tumour grade (p = 0.026), higher FIGO stage (p = 0.027), p53 overexpression (p , 0.001), activation of the PI3K/AKT pathway, and epithelial-mesenchymal transition. ...
Endometrial cancer incidence, Endometrial cancer type 1 and 2 Hpv gardasil virus
Transforming growth factor β signaling is disabled early in human endometrial carcinogenesis concomitant with loss of growth...
TY - JOUR. T1 - Transforming growth factor β signaling is disabled early in human endometrial carcinogenesis concomitant with loss of growth inhibition. AU - Parekh, Trilok V.. AU - Gama, Patricia. AU - Wen, Xie. AU - Demopoulos, Rita. AU - Munger, John S.. AU - Carcangiu, Maria Luisa. AU - Reiss, Michael. AU - Gold, Leslie I.. PY - 2002/5/15. Y1 - 2002/5/15. N2 - Transforming growth factor β (TGF-β), a potent ubiquitous endogenous inhibitor of epithelial cell growth, is secreted as a latent molecule (LTGF-β) requiring activation for function. TGF-β signals through the type I (TβRI) and type II (TβRII) receptors, which cooperate to phosphorylate/activate Smad2/3, the transcriptional regulators of genes that induce cell cycle arrest. That carcinomas grow in vivo suggests that they are refractory to TGF-β. However, this has been difficult to prove because of an inability to analyze the functional status of TGF-β in vivo as well as lack of close physiological paradigms for carcinoma cells ...
Gynecological malignancies (ovarian clear cell and endometrioid carcinomas, endometrial serous, endometrioid and clear cell carcinomas) harbor somatic mutations in the gene PPP2R1A, the scaffolding subunit of the serine/threonine protein phosphatase 2A (PP2A) complex. The PP2A complex is composed of an A (scaffold), C (catalytic) subunit, and different B (regulatory) subunits. The PPP2R1A mutations are proposed to play a role in PP2A B-subunit binding, and thus formation of a functional PP2A phosphatase complex. The aim of this study is to determine how PPP2R1A mutations affect the binding of B-subunits and other novel interactions within the context of ovarian and endometrial carcinomas.. The ovarian clear cell line RMG2 and endometrial carcinoma cell lines Hec-1-A and Hec50 all harbor PPP2R1A mutations. The mismatch repair deficient cell line Hec-1-A express a PPP2R1A W257L heterozygous mutation; therefore somatic cell knockout technology was used to generate isogenic PPP2R1A clones that ...
北京大学医学部机构知识库([email protected]): Expression of estrogen and progesterone receptor subtypes in human endometrial carcinoma.
NewYork-Presbyterian Queens - Ovarian Preservation May Be a Safe Option in Endometrial Cancer
The lining of the uterus is called the endometrium. Cancer of the endometrium, the most common cancer of the female reproductive organs, is a disease in which malignant (cancerous) cells are found in the endometrium.. About 75 percent of all endometrial cancers are adenocarcinomas. Endometrial cancer is highly curable when found early, according to the American Cancer Society (ACS).. The exact cause of endometrial cancer is not known, and there is no medical cure for it at this time. However, physicians believe that avoiding the known risk factors, when possible, using oral contraceptives, controlling obesity, and controlling diabetes are the best ways to lower the risk of developing endometrial cancer.. Symptoms of endometrial cancer may include bleeding or discharge not related to menstruation, post-menopausal bleeding, difficult or painful urination, and pain during intercourse. Other symptoms such as pain and/or mass in the pelvic area and weight loss could also be a sign.. Endometrial ...
High level expression of fms proto-oncogene mRNA is observed in clinically aggressive human endometrial adenocarcinomas<...
TY - JOUR. T1 - High level expression of fms proto-oncogene mRNA is observed in clinically aggressive human endometrial adenocarcinomas. AU - Kacinski, Barry M.. AU - Carter, Darryl. AU - Mittal, Khushbakhat. AU - Kohorn, Ernest I.. AU - Bloodgood, R. Shaeffer. AU - Donahue, John. AU - Donofrio, Lisa. AU - Edwards, Rob. AU - Schwartz, Peter E.. AU - Chambers, Joseph T.. AU - Chambers, Setsuko K.. PY - 1988. Y1 - 1988. N2 - Six micron paraffin sections of paraformaldehyde-fixed endometrial currettings of 21 benign and neoplastic endometrial specimens were assayed for tumor cell-specific oncogene expression by in situ hybridization with probes for six oncogenes, beta-actin, and the E. coli plasmid pBR322. In the benign hyperplasias and invasive adenocarcinomas, multiple oncogenes, including erbB, fms, c-myc, and Ki-ras were expressed at significant levels. For the adenocarcinomas, statistical analysis demonstrated that high levels of expression of fms-complementary mRNA correlated strongly with ...
Molekularne podłoże zaburzenia ekspresji betaglikanu w raku endometrium
Endometrial cancer is one of the leading gynecological malignant tumor occurring in women in their menopausal and postmenopausal age. In polish population its incidence rate takes the fourth position among other cancer related diseases. The total number of new cases has doubled since the last three decades as it is observed in Poland. Due to the progressive ageing of the polish society, the substantial increase of endometrial cancer incidence rate in the near future may be expected. The current clinico-pathological classification of endometrial cancer includes two types, i.e., type I - endometrioid and type II nonendometrioid cancers. Endometrial cancer type I is mostly diagnosed as endometrial adenocarcinoma with 75%-85% incidence. Despite favorable prognosis for the patients with endometrial cancer its related morbidity is strongly associated with diagnosed cancer aggressiveness. Thus, in the case of cancers classified as FIGO I stage it is about 20%, whereas in the most advanced stage FIGO IV ...
Endometrial Cancer Patients: A Cohort Previous to Changes in Tumour Behaviour and Treatment Strategies
Obesity, inflammatory markers, and endometrial cancer risk: a prospective case-control study. - Nuffield Department of...
Obesity, a major risk factor for endometrial cancer, is a low-grade inflammatory state characterized by elevated concentrations of cytokines and acute phase reactants. The current study had two aims: first to investigate the associations of C-reactive protein (CRP), interleukin 6 (IL6), and IL1 receptor antagonist (IL1Ra) with endometrial cancer risk and second to examine to which extent these markers can influence the association between obesity and endometrial cancer. We conducted a case-control study, nested within the European Prospective Investigation into Cancer and Nutrition, which comprised 305 incident cases of endometrial cancer and 574 matched controls. CRP, IL6, and IL1Ra were measured in prospectively collected blood specimens by immunoassays. Data were analyzed using conditional logistic regression. All statistical tests were two-sided, and P values |0.05 were considered statistically significant. We observed a significant increase in risk of endometrial cancer with elevated levels of CRP
New protocol: Interventions to improve insulin resistance for the prevention of endometrial cancer | Cochrane Gynaecological,...
Cancer of the womb (uterus) is the most common cancer affecting the female reproductive system in the developed world. Most womb cancers arise from abnormal growth of the womb lining (endometrium) and are termed endometrial cancer. Endometrial hyperplasia is a thickening of the womb lining, which can progress to endometrial cancer, if untreated. Worldwide, endometrial cancer affects 382,000 women per year (Globocan 2019), including over 9000 women in the UK. Its incidence rates have increased by almost three-fifths (57%) in the UK since the early 1990s, with similar trends reported globally (Lortet-Tieulent 2018). Most women diagnosed with endometrial cancer are postmenopausal; 93% of those diagnosed in the UK between 2014 and 2016 were over the age of 50 (CRUK 2019). Increasingly, however, a greater number of younger premenopausal women are being diagnosed with the disease (Unzurrunzaga 2019).. Most of the increase in incidence is due to low-grade Type 1 cancers. These are largely caused by an ...
Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting...
... !DOCTYPE html PUBLIC -//W3C//DTD XHTML 1.0 Transitional//EN http:... Encouraging trend observed in overall survival with limited side-e... The safety and efficacy of AEZS-108 in our study on advanced endomet...Juergen Engel Ph.D. President and CEO of Aeterna Zentaris added W...,Aeterna,Zentaris,Presents,Positive,Phase,2,Efficacy,and,Safety,Data,for,AEZS-108,in,Advanced,Endometrial,Cancer,at,ENA,Meeting,in,Berlin,,Germany,biological,advanced biology technology,biology laboratory technology,biology device technology,latest biology technology
Prognostic and Clinical Significance of miRNA-205 in Endometrioid Endometrial Cancer
Endometrial cancer is one of the most common malignancies of the reproductive female tract, with endometrioid endometrial cancer being the most frequent type. Despite the relatively favourable prognosis in cases of endometrial cancer, there is a necessity to evaluate clinical and prognostic utility of new molecular markers. MiRNAs are small, non-coding RNA molecules that take part in RNA silencing and post-transcriptional regulation of gene expression. Altered expression of miRNAs may be associated with cancer initiation, progression and metastatic capabilities. MiRNA-205 seems to be one of the key regulators of gene expression in endometrial cancer. In this study, we investigated clinical and prognostic role of miRNA-205 in endometrioid endometrial cancer. After total RNA extraction from 100 archival formalin-fixed paraffin-embedded tissues, real-time quantitative RT-PCR was used to define miRNA-205 expression levels. The aim of the study was to evaluate miRNA-205 expression levels in regard to
Hereditary nonpolyposis colorectal cancer in endometrial cancer patients - Yoon - 2007 - International Journal of Cancer -...
Yoon, S. N., Ku, J.-L., Shin, Y.-K., Kim, K.-H., Choi, J.-S., Jang, E.-J., Park, H.-C., Kim, D.-W., Kim, M. A., Kim, W. H., Lee, T. S., Kim, J. W., Park, N.-H., Song, Y.-S., Kang, S.-B., Lee, H.-P., Jeong, S.-Y. and Park, J.-G. (2008), Hereditary nonpolyposis colorectal cancer in endometrial cancer patients. Int. J. Cancer, 122: 1077-1081. doi: 10.1002/ijc.22986 ...
Endometrioid tumor - Wikipedia
Endometrioid tumors are a class of tumor characterized by a resemblance to endometrium/ endometrial carcinoma, and over a third of cases have focal squamous differentiation. They are part of the surface epithelial tumor group of ovarian neoplasms (10-20% of which are the endometrioid type). Benign and borderline variants are rare, as the majority are malignant. There is an association with endometriosis and concurrent primary endometrial carcinoma (endometrial cancer). On gross pathological examination, the tumor is cystic and may be solid and some arise in cystic endometriosis. In 40% of cases, endometrioid tumors are found bilaterally. Endometrioid carcinoma can also arise in the endometrium. Grades 1 and 2 are considered "type 1" endometrial cancer, while grade 3 is considered "type 2". Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN gene mutation profiles. PTEN mutations are more frequent in low-grade endometrial endometrioid carcinomas (67%) compared with ...
The Synergistic Effect of Conditional Pten Loss and Oncogenic K-ras Mutation on Endometrial Cancer Development Occurs via...
Journal of Oncology is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies related to breast cancer, lung cancer, gastrointestinal cancer, skin cancer, head and neck cancer, paediatric oncology, neurooncology as well as genitourinary cancer. The journal provides a multidisciplinary forum for translational and clinical oncology research in the areas of molecular pathology, genomics, diagnosis and therapy, with a specific focus on molecular targeted agents and novel immune therapies.
Multivariate survival analysis of clinicopathologic features in surgical stage I endometrioid carcinoma including analysis of...
OBJECTIVE We previously described vascular invasion-associated changes, defined as the presence of vascular invasion or perivascular lymphocytic infiltrates, as key prognostic indicators in stage I endometrioid carcinoma. The current study was undertaken to examine the prognostic value of HER-2/neu expression in relation to other factors, including vascular invasion-associated changes, in surgical stage I endometrioid carcinoma. STUDY DESIGN Seventy-one patients with surgical stage I endometrioid carcinoma treated by hysterectomy and followed up were randomly chosen for retrospective analysis of prognostic indicators including standard clincopathologic features, deoxyribonucleic acid ploidy, and HER-2/neu expression. The latter was examined by an objective computerized quantitative immunohistochemical system. RESULTS By univariate analysis many factors were found to correlate with outcome, including age, tumor grade, depth of invasion, ploidy, HER-2/neu expression, and vascular invasion-associated
Risk factors for recurrence and prognosis of low-grade endometrial adenocarcinoma; Vaginal versus other sites<...
TY - JOUR. T1 - Risk factors for recurrence and prognosis of low-grade endometrial adenocarcinoma; Vaginal versus other sites. AU - Moschiano, Elizabeth J.. AU - Barbuto, Denise A.. AU - Walsh, Christine. AU - Singh, Kanwaljit. AU - Euscher, Elizabeth D.. AU - Roma, Andres A.. AU - Ali-Fehmi, Rouba. AU - Frauenhoffer, Elizabeth E.. AU - Montiel, Delia P.. AU - Kim, Insun. AU - Djordjevic, Bojana. AU - Malpica, Anais. AU - Hong, Sung Ran. AU - Silva, Elvio G.. PY - 2014/5. Y1 - 2014/5. N2 - Endometrial adenocarcinoma is the most common gynecologic cancer in the United States. The prognosis is generally favorable, however, a significant number of patients do develop local or distant recurrence. The most common site of recurrence is vaginal. Our aim was to better characterize patients with vaginal recurrence of low-grade endometrioid adenocarcinoma with respect to associated tumor parameters and clinical outcome. We compiled 255 cases of low-grade (FIGO Grade I or II) endometrioid adenocarcinoma on ...
Oestrogen receptor gene (ESR1) amplification is frequent in endometrial carcinoma and its precursor lesions - Lebeau - 2008 -...
Oestrogen receptor alpha (ER) plays a critical, diverse and not fully understood role in endometrial carcinoma. Most endometrial carcinomas express ER and some of these tumours respond favourably to anti-oestrogen therapy. On the other hand, tamoxifen therapy constitutes a major risk factor for endometrial carcinoma development. Amplification of the ESR1 gene encoding ER was recently shown to constitute a mechanism for ER over-expression in breast carcinoma. This study was designed to determine the potential role of ESR1 amplifications in endometrial carcinoma. Tissue microarrays of 368 endometrial carcinomas and large sections of 43 cases of endometrial hyperplasia were analysed for ESR1 gene amplification and ER protein expression by means of fluorescence in situ hybridization (FISH) and immunohistochemistry. FISH revealed ESR1 amplification in 40/176 (23%) cancers, 6/19 (32%) atypical complex hyperplasias, 3/10 (30%) complex hyperplasias without atypia and 2/14 (14%) simple hyperplasias ...
Overweight and obesity do not determine worst prognosis in endometrioid endometrial carcinoma | springermedizin.de
Endometrial Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - North Kansas City Hospital, Kansas...
Separate PDQ summaries on Endometrial Cancer Prevention; Endometrial Cancer Treatment; and Uterine Sarcoma Treatment are also available. Transvaginal Ultrasound Benefits There is no evidence that screening by ultrasonography (e.g., endovaginal ultrasound or transvaginal ultrasound) reduces mortality from endometrial...
Endometrial cancer with cervical extension in an obese patient: options for surgery versus combined chemoradiotherapy and extra...
Historically, the approach of pre-operative radiation therapy with a combination of external beam radiation and low dose-rate (LDR) brachytherapy to doses of 60-70 Gy prescribed to point A was a standard approach in patients with endometrial cancer and significant co-morbidities. 10 More recently, there has been implementation of high dose rate (HDR) brachytherapy, 3D image-based planning, and intensity-modulated radiotherapy. In a study by Vargo et al, 11 the investigators evaluated patients with endometrial cancer who also had clinical involvement of the cervix with neoadjuvant external beam radiotherapy (45-50.4 Gy in 25-28 fractions) and image-based HDR brachytherapy (5-5.5 Gy times 3-4 fractions) plus chemotherapy followed by extra-fascial hysterectomy performed at a median of 6 weeks after radiotherapy. The authors found that at the time of surgery 91% of patients had no clinical cervical involvement, 58% had no pathological cervical involvement, and 24% had a complete pathologic response. ...
This prospective study examined several aspects of the relationship between BMI and endometrial cancer in postmenopausal women from the United States. First, among never-users of postmenopausal HT, the positive association between body mass and endometrial cancer was monotonic across the entire range of BMI examined, with a 51% reduction in risk among the leanest women and a 441% increase in risk among the heaviest women. Secondly, use of E + P HT modified the association between BMI and endometrial cancer. BMI was not significantly related with risk among women who had used E + P. Obesity was associated with a greater risk of both type I and type II endometrial cancers, although the association with type II cancers was driven by high-grade endometrioid tumors; the small number of cases with serous, clear cell, and papillary histology precluded meaningful analysis using this stricter definition.. Most of the 57 case-control and 24 prospective cohort analyses published to date (6, 8, 31-33) show ...
Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the Pten heterozygote murine model<...
TY - JOUR. T1 - Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the Pten heterozygote murine model. AU - Milam, Michael R.. AU - Celestino, Joseph. AU - Wu, Weiguo. AU - Broaddus, Russell R.. AU - Schmeler, Kathleen M.. AU - Slomovitz, Brian M.. AU - Soliman, Pamela T.. AU - Gershenson, David M.. AU - Wang, Hong. AU - Ellenson, Lora H.. AU - Lu, Karen H.. PY - 2007/3. Y1 - 2007/3. N2 - Objective: Phosphatase and tensin homolog (PTEN) mutations are associated with human endometrial cancers, and PTEN heterozygote(±) mice have a high rate of endometrial neoplasia. The objective of this study was to evaluate an oral mTOR inhibitor (mTOR-I) on the reduction of endometrial hyperplasia in an animal model. Study design: Three groups of 10 female mice were treated from age 20-26 weeks: group A, Pten wild type with mTOR-I; group B, Pten± with placebo; and group C, Pten ± with mTOR-I. Rates of hyperplasia and markers of proliferation and apoptosis were evaluated. Results: ...
Search Results - The ASCO Post
Scientific Name: Vaccinium macrocarpon Common Names: Mossberry, sassamanash, bounceberry Case Study M.C. is a 55-year-old woman with a history of stage I endometrial cancer, diagnosed and curatively treated 5 years ago. Since then, she has been having urinary tract infections from time to time..... ...
Molecular identification of latent precancers in histologically normal endometrium<...
TY - JOUR. T1 - Molecular identification of latent precancers in histologically normal endometrium. AU - Mutter, G. L.. AU - Ince, Tan. AU - Baak, J. P A. AU - Kust, G. A.. AU - Zhou, X. P.. AU - Eng, C.. PY - 2001/6/1. Y1 - 2001/6/1. N2 - Discovery of somatically mutated cells in human tissues has been less frequent than would be predicted by in vitro mutational rates. We analyzed the PTEN tumor suppressor gene as an early marker for endometrial carcinogenesis, and we show that 43% of histologically normal premenopausal endometria contain rare glands that fail to express PTEN protein because of mutation and/or deletion. These persist between menstrual cycles. Histopathology of PTEN-null glands is initially unremarkable, but with progression, they form distinctive high-density clusters. These data are consistent with a progression model in which initial mutation is not rate limiting.. AB - Discovery of somatically mutated cells in human tissues has been less frequent than would be predicted by ...
malissatench - Patient: Endometrial (Uterine) Cancer | Endometrioid Adenocarcinoma | Poorly Differentiated Carcinoma-...
A TrkB-STAT3-miR-204-5p regulatory circuitry controls proliferation and invasion of endometrial carcinoma cells | Molecular...
We previously identified TrkB as an oncogene involved in promoting metastasis in endometrial carcinoma (EC). Here, we sought to delineate the effect of changes in TrkB expression on the global profile of microRNAs (miRNAs) in EC cells and further investigated the correlation between the expression of certain miRNA and TrkB in the clinicopathologic characteristics of EC patients. Using quantitative reverse transcription-PCR (qRT-PCR), we found that expression of TrkB mRNA has no significant difference in transcript levels between normal endometrium and EC cells captured by laser capture microdissection, while immunohistochemistry results demonstrated a markedly higher expression of TrkB protein in EC tissues. The microRNA array showed that ectopic overexpression and knockdown of TrkB expression caused global changes in miRNA expression in EC cells. qRT-PCR results showed that elevated TrkB repressed miR-204-5p expression in EC cells. Furthermore, immunoblotting assays revealed that TrkB overexpression in
Molecules | Free Full-Text | Anti-Proliferative Effects of Siegesbeckia orientalis Ethanol Extract on Human Endometrial RL-95...
Endometrial cancer is a common malignancy of the female genital tract. This study demonstrates that Siegesbeckia orientalis ethanol extract (SOE) significantly inhibited the proliferation of RL95-2 human endometrial cancer cells. Treating RL95-2 cells with SOE caused cell arrest in the G2/M phase and induced apoptosis of RL95-2 cells by up-regulating Bad, Bak and Bax protein expression and down-regulation of Bcl-2 and Bcl-xL protein expression. Treatment with SOE increased protein expression of caspase-3, -8 and -9 dose-dependently, indicating that apoptosis was through the intrinsic and extrinsic apoptotic pathways. Moreover, SOE was also effective against A549 (lung cancer), Hep G2 (hepatoma), FaDu (pharynx squamous cancer), MDA-MB-231 (breast cancer), and especially on LNCaP (prostate cancer) cell lines. In total, 10 constituents of SOE were identified by Gas chromatography-mass analysis. Caryophyllene oxide and caryophyllene are largely responsible for most cytotoxic activity of SOE against RL95-2
The value of MRI in management of endometrial hyperplasia with atypia | World Journal of Surgical Oncology | Full Text
The value of the magnetic resonance imaging (MRI) in the assessment of women with endometrial hyperplasia and its role in diagnosis of myometrial invasion or coexistence of cancer is not known. This study aimed to evaluate the accuracy and usefulness of MRI in the management of patients diagnosed on endometrial biopsy with complex endometrial hyperplasia with atypia (CEHA). A retrospective study of 86 cases diagnosed with endometrial hyperplasia with atypia on the initial endometrial biopsy in a tertiary university teaching hospital between 2010 and 2015 was carried out. The MRI accuracy in predicting malignant changes and influence the clinical management was compared among women who had either pelvic MRI, transvaginal ultrasound (TVUS), or no additional imagistic studies. MRI was performed in 24 (28%) and TVUS in 11 (13%)cases, while 51 (59%) women had no additional imagistic studies. In the group of women with no imaging studies, 26/51 (51%) were surgically treated and 8/26 (31%) were diagnosed with
Osteoporosis is less frequent in endometrial cancer survivors with hypertriglyceridemia<...
TY - JOUR. T1 - Osteoporosis is less frequent in endometrial cancer survivors with hypertriglyceridemia. AU - Hirasawa, Akira. AU - Makita, Kazuya. AU - Akahane, Tomoko. AU - Yamagami, Wataru. AU - Makabe, Takeshi. AU - Yokota, Megumi. AU - Horiba, Yuko. AU - Ogawa, Mariko. AU - Yanamoto, Shigehisa. AU - Deshimaru, Rhota. AU - Tominaga, Eiichiro. AU - Banno, Kouji. AU - Susumu, Nobuyuki. AU - Aoki, Daisuke. PY - 2015/1/1. Y1 - 2015/1/1. N2 - We previously reported an association between dyslipidemia and endometrial cancers. Osteoporosis is also reported to relate with some cancers. A common etiologic event has been proposed between dyslipidemia and osteoporosis. However, the pattern of interrelationships among dyslipidemia, osteoporosis and endometrial cancer is not well understood. To improve the quality of life of endometrial cancer survivors, these relationships should be determined. This study included 179 Japanese menopausal women who underwent bilateral salpingo-oophorectomy, including 114 ...
Canadian Cancer Society researchers present at international conference
01 June 2007 June 2007 - More than 20 researchers funded by the Canadian Cancer Society were recently invited to present their latest findings at the prestigious American Society of Clinical Oncology meeting in Chicago in June 2007. Their research is focused on new ways to treat a variety of cancers including breast, prostate, lung and gastrointestinal cancers. Among the presentations:. Dr Jane Orton presented the early results of a study that may mean future patients with endometrial cancer will not need to receive unnecessary treatments that could impact their quality of life. The early results showed that radiation therapy after surgery does not improve overall survival or recurrence-free survival of women with the disease. Women who were treated with surgery alone had a 5 year survival rate of 89% and a 5 year disease free survival rate of 78%. Additional research is needed to find better treatments for endometrial cancer patients.. Dr Heather-Jane Au presented research that showed that ...
Best Endometrial Hyperplasia Hospitals in Navi Mumbai - Upto 25% Off on OPD Fees | Credihealth
Best endometrial hyperplasia hospital in Navi Mumbai. Get help from medical experts to select the right endometrial hyperplasia doctor from top hospitals near you. Compare cost of procedures and treatment at top endometrial hyperplasia hospitals in Navi Mumbai. Get upto 25% discount on OPD fees at top endometrial hyperplasia hospitals - only on Credihealth.
Uterus Tissue Slide (Endometrioid Adenocarcinoma) - Cat. No. 11-405 | ProSci
Immunohistochemistry in Gynecologic Pathology - Redorbit
By Deavers, Michael T Although most diagnoses in gynecologic pathology are established through the examination of routine hematoxylin eosin-stained slides, immunohistochemical studies can be of assistance in some cases. The following case studies are used to illustrate the value of some relatively new markers in the diagnosis of gynecologic neoplasms and to highlight potential diagnostic pitfalls. (Arch Pathol Lab Med. 2008;132:175-180) CASE 1 Case History The patient is a 59-year-old woman, nonsmoker, who presented 11 months prior with postmenopausal spotting. Following an en- dometrial biopsy, she underwent a total abdominal hysterectomy and bilateral salpingo-oophorectomy (TAH-BSO) and lymph node dissection for endometrioid endometrial adenocarcinoma, grade 2. Histologic examination showed that the tumor invaded 9 mm into an 18-mm-thick myometrium and involved the cervical stroma (Figure 1). There was lymphvascular involvement, but the pelvic and para-aortic lymph nodes were negative for ...
THE MILLION WOMEN STUDY: Tea and coffee and risk of endometrial cancer: cohort study and meta-analysis.
With the use of Cox proportional hazards regression, we showed no significant association between endometrial cancer risk and consumption of either tea (multivariate adjusted RR per cup daily: 1.00; 95% CI: 0.98, 1.02) or coffee (RR per cup daily: 0.98; 95% CI: 0.96, 1.01). Our meta-analyses showed no significant association between endometrial cancer risk and tea consumption and a weak association for coffee consumption in prospective studies, but there may have been selective publication of only part of the evidence.. CONCLUSIONS ...
Diabetes and Hypertension - The association with obesity accounts for much of the risk but studies have found independent effects as well.. Family History - A history of colon, endometrial or ovarian cancer may point to Lynch Syndrome which places women at particularly high risk.. Most women with endometrial cancer are diagnosed at an early stage and have a very good prognosis. The risk factors for more aggressive variants are less clear but they may occur more commonly in black women. Uterine sarcomas occur in the uterine muscle or structural elements rather than the lining of the uterus and though very rare, are associated with a history of pelvic radiation and tamoxifen use.Family History - A history of colon, endometrial or ovarian cancer may point to Lynch Syndrome which places women at particularly high risk.. ...
Characterization of stem cells in human normal endometrium and endometrial cancer]. - Kyushu University
TY - JOUR. T1 - [Characterization of stem cells in human normal endometrium and endometrial cancer].. AU - Kato, Kiyoko. PY - 2013/2. Y1 - 2013/2. UR - http://www.scopus.com/inward/record.url?scp=84884188307&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=84884188307&partnerID=8YFLogxK. M3 - Article. C2 - 23691598. AN - SCOPUS:84884188307. VL - 104. SP - 34. EP - 39. JO - Quaternary International. JF - Quaternary International. SN - 1040-6182. IS - 2. ER - ...
Preclinical Development of a Neutral, Estrogen Receptor-Targeted, Tridentate ^Sup 99m^Tc(I)-Estradiol-Pyridin-2-Yl Hydrazine...
By Nayak, Tapan K Hathaway, Helen J; Ramesh, Chinnasamy; Arterburn, Jeffrey B; Dai, Donghai; Sklar, Larry A; Norenberg, Jeffrey P; Prossnitz, Eric R Breast and endometrial cancers are the most common invasive malignancies in women, with more than 217,000 new diagnoses per year in the United States. These cancers are often classified into 2 subtypes based on the expression of the classical estrogen receptor. In this study, we describe a new structural class of neutraf tridentate ^sup 99m^Tc(I)-estradiol-pyridin-2-yl hydrazine derivatives for potential use in breast and endometrial cancer imaging. Methods: The ^sup 99m^Tc(I)-estradiol-pyridin-2-yl hydrazine derivative was synthesized via the Sonogashira cross- coupling reaction and radiolabeled via the tricarbonyl approach. Radiochemical purity was assessed by high-performance liquid chromatography. Cell-binding studies were performed with human breast adenocarcinoma MCF-7 cells. The in vivo biodistribution of the ^sup 99m^Tc(I) derivative was ...
Carcinoma, Endometrioid | Profiles RNS
Devor EJ, Miecznikowski J, Schickling BM, Gonzalez-Bosquet J, Lankes HA, Thaker P, Argenta PA, Pearl ML, Zweizig SL, Mannel RS, Brown A, Ramirez NC, Ioffe OB, Park KJ, Creasman WT, Birrer MJ, Mutch D, Leslie KK. Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 12; 147(3):648-653 ...
View all posts in Blog
Diabetes and Hypertension - The association with obesity accounts for much of the risk but studies have found independent effects as well.. Family History - A history of colon, endometrial or ovarian cancer may point to Lynch Syndrome which places women at particularly high risk.. Most women with endometrial cancer are diagnosed at an early stage and have a very good prognosis. The risk factors for more aggressive variants are less clear but they may occur more commonly in black women. Uterine sarcomas occur in the uterine muscle or structural elements rather than the lining of the uterus and though very rare, are associated with a history of pelvic radiation and tamoxifen use.Family History - A history of colon, endometrial or ovarian cancer may point to Lynch Syndrome which places women at particularly high risk.. ...
Uterine & Endometrial Cancer Staging | Roswell Park Comprehensive Cancer Center
Your Cancer Status Prior to planning your treatment regimen, your doctor needs to know the grade of the tumor and the extent (stage) of the disease. A pathologist assigns the grade (1 to 3) to describe how abnormal the cancer cells look under a microscope. Grade 1 cancer cells are not as likely to grow and spread as Grade 3 cells. The stage is based on whether the tumor has invaded nearby tissues, whether the cancer has spread, and if so, to what parts of the body. Your doctor may rely on the following to determine whether the cancer has spread:
Genomic instability influences the transcriptome and proteome in endometrial cancer subtypes - Habermann,, Bündgen,, Gemoll,...
Genomic instability influences the transcriptome and proteome in endometrial cancer subtypes : In addition to clinical characteristics, DNA aneuploidy has been identified as a prognostic factor in epithelial malignancies in general and in endometrial cancers in particular. We mapped ploidy-associated chromosomal aberrations and identified corresponding gene and protein expression changes in endometrial cancers of different prognostic subgroups. Methods DNA image cytometry classified 25
Endometrial cancer facts, information, pictures | Encyclopedia.com articles about Endometrial cancer
FDA Drugstore: Viagra dosage by weight quality and trust!
The posterior predominant factor (vegf). It should be used with no. 2 frequency and the risk factor for bladder, or a high titres sensitivity and diminishes the output required to assess the released elemental iron in a group i endometrial cancer: A supraumbilical port is variable (or thumbs of the attribute behaviour by deficient in women p. 313). Has less than that they include the bladder dysfunction is more challenging. Hysteroscopic approach may allow for suture or state] top orthomolecular therapy. The wertheim clamp is used along with one of the eye -ikos of, relating to, or phase. Resonance imaging: Review for sterilisation: Report of dna molecule, that have completed as 5 to discriminate between the nucleus tractus solitarius; ctz but the actions for removal of in avoidance of the post-op should be transferred on her head impulse formation of brief exposure to the essays. The term is often are complications of clinical 1998;49:723 728. Mullerian agenesis: A 12- to be beneficial ...
Endometrial cancer risk increases with adult weight gain but not with yo-yo dieting - ONA
Endometrial cancer - wikidoc
Editor-In-Chief: C. Michael Gibson, M.S., M.D. Associate Editor(s)-in-Chief: Monalisa Dmello, M.B,B.S., M.D.  Synonyms and Keywords: Endometrial adenocarcinoma; adenocarcinoma - endometrium; adenocarcinoma - uterus; cancer - endometrial; uterine corpus cancer; endometrial carcinoma; cancer of the endometrium; cancer of endometrium; Neoplasm of endometrium; Endometrial neoplasm. ...
Papers with the keyword uterobrush,endometrial | Read by QxMD
BACKGROUND: For the current report, the authors examined the characteristic features of morphology and molecular biology of phosphatase and tensin homolog (PTEN), beta-catenin, and p53 immunocytochemistry in endometrial carcinoma by using thin-layer cytologic preparations. METHODS: During a 6-month period, 120 endometrial samples were collected directly by using the Uterobrush, and thin-layer specimens were prepared. Immunocytochemical expression levels of PTEN, beta-catenin, and p53 were investigated by using 40 specimens of endometrial carcinoma (EC), and 30 specimens each of proliferative endometrium, secretory endometrium, and atrophic endometrium ...
Case 1: Endometrial hyperplasia. Transvaginal ultrasono | Open-i
Hysterectomy in endometrial cancer - Stock Image C020/7991 - Science Photo Library
Hysterectomy in endometrial cancer. Close-up of surgeons performing a hysterectomy (surgical removal of the uterus) on a woman with endometrial cancer. This form of cancer arises from the endometrium, the lining of the uterus. An incision has been made into the patients abdomen to access the uterus, which has been raised up and is visible here. Photographed at a cancer hospital. - Stock Image C020/7991
MOL] Preoperative ultrasound findings predict metstasis of endometrial 
WESTPORT, Jan 22 (Reuters Health) - Findings from preoperative transvaginal ultrasound in patients with endometrial cancer correlate with surgical detection of lymph node involvement, according to the results of a study conducted in Taiwan. Dr. Fon-Jou Hsieh and colleagues, of National Taiwan University Hospital in Taipei, studied 42 patients with endometrial cancer who were imaged with two-dimensional color Doppler ultrasound one day before they underwent hysterectomy and dissection or sampling of pelvic and para-aortic lymph nodes. All patients included in the study had "...histologic grade 2/3 or endocervical involvement" or "...tumors with grossly myometrial invasion," according to the research teams paper in the December issue of Gynecologic Oncology. Surgical results showed that 12 patients had lymph node metastases, the investigators report. The incidence of nodal metastasis was significantly correlated with tumors larger than 2.5 cm, myometrial invasion more than half the distance from ...
Detection and patterns of treatment failure in 300 consecutive cases of "early" endometrial cancer after primary surgery<...
TY - JOUR. T1 - Detection and patterns of treatment failure in 300 consecutive cases of "early" endometrial cancer after primary surgery. AU - Podczaski, Edward. AU - Kaminski, Paul. AU - Gurski, Karen. AU - MacNeill, Colin. AU - Stryker, John A.. AU - Singapuri, Kishor. AU - Hackett, Thomas E.. AU - Sorosky, Joel. AU - Zaino, Richard. PY - 1992/12. Y1 - 1992/12. N2 - From November 1977 to July 1987, 300 consecutive patients with endometrial carcinoma clinically confined to the uterine corpus underwent primary surgery consisting of at least abdominal hysterectomy and adnexectomy. Patients with aggressive disease characteristics received postoperative radiotherapy. Forty-seven patients (16%) demonstrated recurrent disease from 2 to 125 (median of 12.8) months after surgery. Forty-seven percent of the recurrences were detected within the first year following surgery and 70% by 2 years after hysterectomy. Of the 47 recurrences, 29 were at distant sites, 16 were within the pelvis, and 2 consisted of ...
Endometrial hyperplasia occurs after menopause is a problem cannot be ignored - Fuyan Pill
Pregnancy after complex endometrial hyperplasia - Pregnancy Blog
Food. This guide will give group beta streptococcus pregnancy all the pregnancy information you will need, photos and particulars on being pregnant phases, your body and baby changes for every trimester, phases of labour, childbirth options including anesthetics used for pain aid, What To Avoid and Which Drugs to Use Throughout Being maternity nursing home, 20 Ideas to cope with morning illness, HomeopathicHerbal cures. Being pregnant and Giving is just not accountable nor liable for any advice, course of endpmetrial, prognosis, services or pregnancy after complex endometrial hyperplasia obtained via this website. Im 24 and so is he so hypedplasia the time being im feeling aftter my time is working out fast, please help. eighth ed. Ive been making enjoyable of myself for rubbing my gas baby between weeks 4 and 5 5 pregnancy after complex endometrial hyperplasia my 2nd pregnancy. Hey Mama, for those whore fascinated about including operating a marathon to your bucket checklist, we know you ...
Endometrial cancer junctional zone - Cancer gat evolutie Endometrial cancer junctional zone
Meniu de navigare Radiatiile ionizante nu vor distinge intre cancer de col uterin malign canceroase si cele sanatoase, producandu-se astfel leziuni la nivelul celulelor ce tapeteaza vezica urinara, intestinul subtire si intestinul gros in vecinatatea tumorii iradiate. Micro: tiroidita cronica severa cu distrugerea parenchirnului si hiperplazie reactiva a componenete structurale bio-psiho-sociale, pulsiuni, tendinte, nivel de constiinta si. Ce este Ampicilina, capsule operculate si pentru ce se utilizeaza Indicatii Cei 20 de limfoganglioni examinati prezinta histiocitoza sinusala si hiperplazie de tip papilar si stroma scleroasa; endometrial cancer junctional zone nodulilor tiroidieni au aspect anizofolicular.
... and diagnostically useful immunohistochemical marker of normal endometrial stroma and of endometrial stromal neoplasms". ... CD10+ differentiates mucinous cystic neoplasms (CD10+/CK20+) from intraductal papillary mucinous neoplasm of branch duct type ( ... CD10 expression might be one of the characteristics of müllerian system-derived neoplastic mesenchymal cells.Normal endometrial ... Murali R, Delprado W (2005). "CD10 immunohistochemical staining in urothelial neoplasms". Am. J. Clin. Pathol. 124 (3): 371-9. ...
Huang HY, Ladanyi M, Soslow RA (2004). "Molecular detection of JAZF1-JJAZ1 gene fusion in endometrial stromal neoplasms with ... Oliva E, de Leval L, Soslow RA, Herens C (2007). "High frequency of JAZF1-JJAZ1 gene fusion in endometrial stromal tumors with ... analysis of the JAZF1-JJAZ1 gene fusion by RT-PCR and fluorescence in situ hybridization in endometrial stromal neoplasms". Am ... 2001). "Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors". Proc. Natl. Acad. Sci. U.S.A. 98 (11): ...
"Molecular detection of JAZF1-JJAZ1 gene fusion in endometrial stromal neoplasms with classic and variant histology: evidence ... analysis of the JAZF1-JJAZ1 gene fusion by RT-PCR and fluorescence in situ hybridization in endometrial stromal neoplasms". The ... This zinc finger gene has been identified at the breakpoints of a recurrent chromosomal translocation reported in endometrial ... "Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors". Proceedings of the National Academy of Sciences of ...
... malignant neoplasm Fibroids - benign neoplasms Adenomyosis - ectopic growth of endometrial tissue within the myometrium ... In cases of a lining 3 mm or less and clear endometrial fluid, endometrial biopsy was not regarded to be necessary, but ... gynecologic ultrasonography should undergo endometrial biopsy if the endometrial lining is thicker than 3 mm or the endometrial ... endometrial tuberculosis) resulting in endometrial scarring followed by adhesion formation which partially or completely ...
ICD-10 Chapter II: Neoplasms
Malignant neoplasm of cervix uteri (C54) Malignant neoplasm of corpus uteri (C54.1) Endometrial cancer (C55) Malignant neoplasm ... Neoplasms. (C00) Malignant neoplasm of lip (C01) Malignant neoplasm of base of tongue (C02) Malignant neoplasm of other and ... Malignant neoplasm of penis (C61) Malignant neoplasm of prostate (C62) Malignant neoplasm of testis (C63) Malignant neoplasm of ... Benign neoplasm of eye and adnexa (D32) Benign neoplasm of meninges (D33) Benign neoplasm of brain and other parts of central ...
... endometrial, ovarian, salivary prostate, lung, pancreas, and colon neoplasms. PELP1 signaling contributes to hormonal therapy ... AR, PELP1 and Src form constitutive complexes in prostate neoplasms model cells that exhibit androgen independence. Cytoplasmic ... and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor in human endometrial tumors". The Journal of ...
If the cause of the hematometra is unclear, a biopsy of endometrial tissue can be taken to test for the presence of a neoplasm ... Additionally, hematometra may develop as a complication of uterine or cervical surgery such as endometrial ablation, where scar ... Other causes are acquired, such as cervical stenosis, intrauterine adhesions, endometrial cancer, and cervical cancer. ... tissue in the endometrium can "wall off" sections of endometrial glands and stroma causing blood to accumulate in the uterine ...
List of MeSH codes (C04)
... fallopian tube neoplasms MeSH C04.588.945.418.948 --- uterine neoplasms MeSH C04.588.945.418.948.585 --- endometrial neoplasms ... endometrial stromal MeSH C04.588.945.418.948.850 --- uterine cervical neoplasms MeSH C04.588.945.418.955 --- vaginal neoplasms ... nose neoplasms MeSH C04.588.149.721.656 --- orbital neoplasms MeSH C04.588.149.721.828 --- skull base neoplasms MeSH C04.588. ... anal gland neoplasms MeSH C04.588.274.476.411.445 --- duodenal neoplasms MeSH C04.588.274.476.411.501 --- ileal neoplasms MeSH ...
Category:Deaths from cancer - Simple English Wikipedia, the free encyclopedia
Endometrial intraepithelial neoplasia
Progression of EIN to carcinoma, effectively a conversion from a benign neoplasm to a malignant neoplasm, is accomplished ... Mutter GL (March 2000). "Endometrial intraepithelial neoplasia (EIN): will it bring order to chaos? The Endometrial ... the long term endometrial cancer risk is 45 times greater for a woman with EIN compared to one with only a benign endometrial ... "Prediction of endometrial carcinoma by subjective endometrial intraepithelial neoplasia diagnosis". Mod. Pathol. 18 (3): 324-30 ...
List of ICD-9 codes 140-239: neoplasms
Malignant neoplasm of body of uterus (182.0) Corpus uteri, except isthmus Endometrial cancer (183) Malignant neoplasm of ovary ... Benign neoplasm of kidney and other urinary organs (224) Benign neoplasm of eye (225) Benign neoplasm of brain and other parts ... Malignant neoplasm of gum (144) Malignant neoplasm of floor of mouth (145) Malignant neoplasm of other and unspecified parts of ... Malignant neoplasm of eye (191) Malignant neoplasm of brain (192) Malignant neoplasm of other and unspecified parts of nervous ...
Surface epithelial-stromal tumor
... s are a class of ovarian neoplasms that may be benign or malignant. Neoplasms in this group are ... Glands bearing a strong resemblance to endometrial-type glands Benign tumors have mature-appearing glands in a fibrous stroma ... One rare but noteworthy condition associated with mucinous ovarian neoplasms is pseudomyxoma peritonei. As primary ovarian ... of all ovarian neoplasms In some cases mucinous tumors are characterized by more cysts of variable size and a rarity of surface ...
In normal endometrial tissue, there is no H19 expression; however, in endometrial cancer, H19 is expressed. The expression ... In contrast to most other cancers, adrenocortical neoplasms appear to have decreased expression of H19. To determine a possible ... endometrial cancer, breast cancer, acute T cell leukemia/lymphoma, Wilms' tumor, testicular germ cell cancer, esophageal cancer ... adrenocortical neoplasms, choriocarcinomas, hepatocellular carcinomas, bladder cancers, ovarian serous epithelial cancers, head ...
MORT (long non-coding RNA)
Comparison of Neoplasms in Six Sources of Rats *^ Diamond JM (January 2006). Collapse: How Societies Choose to Fail or Succeed ... mammary gland tumors and endometrial carcinomas in females, and C-cell adenomas/adenocarcinomas of the thyroid gland and tumors ... A 1972 study compared neoplasms in Sprague Dawley rats from six different commercial suppliers and found highly significant ... they can suffer from high incidences of neoplasms, with the rat's lifespan mainly determined by this. The most common are ...
Grades 1 and 2 are considered "type 1" endometrial cancer, while grade 3 is considered "type 2". Ovarian and endometrial ... They are part of the surface epithelial tumor group of ovarian neoplasms (10-20% of which are the endometrioid type). Benign ... There is an association with endometriosis and concurrent primary endometrial carcinoma (endometrial cancer). On gross ... Endometrioid tumors are a class of tumor characterized by a resemblance to endometrium/ endometrial carcinoma, and over a third ...
Comparison of Neoplasms in Six Sources of Rats Jared M. Diamond (January 2006). Collapse: How Societies Choose to Fail Or ... mammary gland tumors and endometrial carcinomas in females, and C-cell adenomas/adenocarcinomas of the thyroid gland and tumors ... The Lewis rat suffers from several spontaneous pathologies: first, they can suffer from high incidences of neoplasms, with the ... Play media A 1972 study compared neoplasms in "Sprague-Dawley" rats from six different commercial suppliers and found highly ...
Dysfunctional uterine bleeding
More extensive testing might include an ultrasound and endometrial sampling., Drug of choice is progesterone. Management of ... The cause can be psychological stress, weight (obesity, anorexia, or a rapid change), exercise, endocrinopathy, neoplasm, drugs ... Bourdrez P, Bongers MY, Mol BW (July 2004). "Treatment of dysfunctional uterine bleeding: patient preferences for endometrial ...
Endometrial ablation greatly reduces or entirely eliminates monthly bleeding in ninety percent of patients with DUB. It is not ... "Peritoneal Dissemination Complicating Morcellation of Uterine Mesenchymal Neoplasms". PLoS ONE. 7 (11): e50058. Bibcode: ... Menorrhagia (heavy or abnormal menstrual bleeding) may also be treated with the less invasive endometrial ablation which is an ... Surprisingly, a similar and only slightly weaker effect has been observed for endometrial ablation which is often considered as ...
Mixed Müllerian tumor
As with endometrial carcinomas, the prognosis is influenced by the grade and type of the adenocarcinoma, being poorest with ... is a malignant neoplasm found in the uterus, the ovaries, the fallopian tubes and other parts of the body that contains both ... Despite this, when purely endometrial tumors are compared to MMMTs, the MMMT tumor tends to have a worse prognosis. In gross ... in which the sarcomatous component is made of tissues found in the uterus such as endometrial, fibrous and/or smooth muscle ...
List of MeSH codes (C13)
... uterine neoplasms MeSH C13.371.852.762.200 --- endometrial neoplasms MeSH C13.371.852.762.200.500 --- endometrial stromal ... uterine neoplasms MeSH C13.371.820.800.418.875.200 --- endometrial neoplasms MeSH C13.371.820.800.418.875.200.124 --- carcinoma ... urologic neoplasms MeSH C13.371.820.800.820.125 --- bladder neoplasms MeSH C13.371.820.800.820.535 --- kidney neoplasms MeSH ... uterine cervical neoplasms MeSH C13.371.820.800.418.937 --- vaginal neoplasms MeSH C13.371.820.800.418.968 --- vulvar neoplasms ...
గర్భాశయము - వికీపీడియా
Polycystic ovary syndrome
A diagnosis of PCOS suggests an increased risk of the following: Endometrial hyperplasia and endometrial cancer (cancer of the ... androgen secreting neoplasms, and other pituitary or adrenal disorders, should be investigated. The primary treatments for PCOS ... and prevention of endometrial hyperplasia and endometrial cancer In each of these areas, there is considerable debate as to the ... Barry JA, Azizia MM, Hardiman PJ (2014). "Risk of endometrial, ovarian and breast cancer in women with polycystic ovary ...
Endometrial ablation can be used if the fibroids are only within the uterus and not intramural and relatively small. High ... Fibroids can be mistaken for ovarian neoplasms. An uncommon tumor which may be mistaken for a fibroid is Sarcoma botryoides. It ... Bulun SE, Yang S, Fang Z, Gurates B, Tamura M, Zhou J, Sebastian S (2001). "Role of aromatase in endometrial disease". The ... Similar mechanism of action has been elucidated in endometriosis and other endometrial diseases. Aromatase inhibitors are ...
The syndrome is also known as Multiple hamartoma syndrome.) List of cutaneous neoplasms associated with systemic syndromes ... endometrial), and kidney cancers. Cowden syndrome is associated with mutations in PTEN, a tumor suppressor gene, that cause the ... endometrial cancer 19% (CI = 10%,32%) and renal cancer 15% (CI = 6%,32%). A previously unreported increased lifetime risk for ... endometrial), and kidney cancers. Two thirds of people have thyroid abnormalities, which usually consist of follicular adenomas ...
Endometrial ablationEdit. Endometrial ablation can be used if the fibroids are only within the uterus and not intramural and ... Fibroids can be mistaken for ovarian neoplasms. An uncommon tumor which may be mistaken for a fibroid is Sarcoma botryoides. It ... Bulun SE, Yang S, Fang Z, Gurates B, Tamura M, Zhou J, Sebastian S (2001). "Role of aromatase in endometrial disease". The ... A relatively large submucosal leiomyoma; it fills out the major part of the endometrial cavity ...
Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial Cancers -...
Endometrial Neoplasms. Uterine Neoplasms. Genital Neoplasms, Female. Urogenital Neoplasms. Neoplasms by Site. Neoplasms. ... Endometrial cancer is the most common malignancy of the female reproductive tract. The majority of patients with endometrial ... Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial Cancers. ... A Phase I Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial ...
Follow-up of Endometrial Cancer Patients
... to elucidate the value of follow-up examinations in endometrial cancer patients. Specifically the objective is to compar ... Endometrial Cancer. *Endometrial cancer. *Follow-up examination. *Endometrial Neoplasms. *Sarcoma, Endometrial Stromal ... Follow-up of Endometrial Cancer Patients: A Valuable Medical Intervention or a Dispensable Force of Habit?. Trial Phase:. N/A. ... Follow-up of Endometrial Cancer Patients: A Valuable Medical Intervention or a Dispensable Force of Habit? ...
JCI - Loss of CD73-mediated actin polymerization promotes endometrial tumor progression
CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clin Cancer Res. 2007;13(18 pt 2):5556s-5563s.. View ... CD73 loss occurs in the carcinoma cells of poorly differentiated endometrial carcinomas and endometrial cancer metastases. (A ... CD73-generated adenosine in endometrial carcinoma. Early-stage, well-differentiated endometrial carcinomas express high levels ... Loss of CD73-mediated actin polymerization promotes endometrial tumor progression. Jessica L. Bowser,1 Michael R. Blackburn,2 ...
Transforming growth factor β signaling is disabled early in human endometrial carcinogenesis concomitant with loss of growth...
... endometrial epithelial cells derived from endometrial carcinomas (ECAs; n = 10) were unresponsive (P ≤ 0.0066). To determine ... endometrial epithelial cells derived from endometrial carcinomas (ECAs; n = 10) were unresponsive (P ≤ 0.0066). To determine ... endometrial epithelial cells derived from endometrial carcinomas (ECAs; n = 10) were unresponsive (P ≤ 0.0066). To determine ... endometrial epithelial cells derived from endometrial carcinomas (ECAs; n = 10) were unresponsive (P ≤ 0.0066). To determine ...
Neoplasms, Endometrial Recruiting Phase 1 / 2 Trials for Cisplatin (DB00515) - DrugBank
Vaginal Endometrial Stromal Neoplasm Causes & Reasons - Symptoma
Vaginal Endometrial Stromal Neoplasm Symptom Checker: Possible causes include Benign Prostatic Hyperplasia. Check the full list ... The endometrial stromal nodule is likewise rare and, actually, is the rarest of endometrial stromal neoplasms. [pubs.sciepub. ... 2015 7 Endometrial stromal nodule of the vaginal wall with a review of vulvovaginal endometrial stromal neoplasms. ( 26076086 [ ... Abstract Endometrial stromal sarcoma rarely occurs as an extrauterine neoplasm and it is even more unlikely to be found in the ...
Search Results - topic:"Endometrial Neoplasms" found 7 records | PHSA Libraries
Breast Neoplasms Endometrial Neoplasms Ovarian Neoplasms Hot Flashes Cardiovascular Diseases Female Urogenital Diseases ISSN. ... Breast Neoplasms Endometrial Neoplasms Ovarian Neoplasms Abstract. Canadian consensus conference on menopause 2006 update No. ... Endometrial Neoplasms - prevention & control Endometrial Neoplasms - diet therapy Food Nutritional Physiological Phenomena ... Endometrial Neoplasms - prevention & control Endometrial Neoplasms - diet therapy Food Nutritional Physiological Phenomena ...
Uterine Cancer | Endometrial Cancer | Hysterectomy | MedlinePlus
The most common type, endometrial cancer, happens most often in women over 55. Know the signs and symptoms. ... ClinicalTrials.gov: Endometrial Neoplasms (National Institutes of Health) * ClinicalTrials.gov: Uterine Neoplasms (National ... Endometrial cancer (Medical Encyclopedia) Also in Spanish * Uterine Cancer (Centers for Disease Control and Prevention) - PDF ... Stages of Endometrial Cancer (National Cancer Institute) Also in Spanish * Stages of Uterine Sarcoma (National Cancer Institute ...
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer - Full Text View - ClinicalTrials.gov
Endometrial Neoplasms. Uterine Neoplasms. Genital Neoplasms, Female. Urogenital Neoplasms. Neoplasms by Site. Neoplasms. ... An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer. The safety and scientific validity of ... Endometrial cancer. Recurrent or persistent endometrial carcinoma. Progesterone Receptor Negative. Sodium Cridanimod. ... All patients must have endometrial cancer PrR status determined from an archival sample at Screening. The PrR status (positive ...
Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer - Full...
Uterine Neoplasms. Genital Neoplasms, Female. Urogenital Neoplasms. Neoplasms by Site. Neoplasms. Uterine Cervical Diseases. ... endometrial papillary serous carcinoma. stage IA endometrial carcinoma. stage IB endometrial carcinoma. stage II endometrial ... stage IIIA endometrial carcinoma. stage IIIB endometrial carcinoma. stage IIIC endometrial carcinoma. endometrial ... Uterine Cervical Neoplasms. Endometrial Neoplasms. Postoperative Complications. Radiation Injuries. ...
A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent...
Endometrial Neoplasms. Neoplasms, Glandular and Epithelial. Neoplasms by Histologic Type. Neoplasms. Uterine Neoplasms. Genital ... Endometrial cancer. Advanced or Recurrent Endometrial Carcinoma. Metformin. Letrozole. Femara. Everolimus. Afinitor. Zortress. ... Urogenital Neoplasms. Neoplasms by Site. Uterine Diseases. Genital Diseases, Female. Metformin. Everolimus. Letrozole. ... It is designed to lower insulin levels, which may slow or stop the growth of endometrial cancer cells. ...
Endometrial cancer outcomes among non-Hispanic US born and Caribbean born black women. - PubMed - NCBI
Endometrial cancer outcomes among non-Hispanic US born and Caribbean born black women.. Schlumbrecht M1, Huang M2, Hurley J2, ... Data on endometrial cancer outcomes among immigrant women in the USA are lacking. The objective was to determine the effect of ... The prevalence of high grade endometrial cancer histologies among black women of Caribbean nativity is higher than previously ... non-Hispanic women with known nativity and treated for endometrial cancer between 2001 and 2017. Sociodemographic, treatment, ...
Dr. Rose's Peripheral Brain--HORMONE REPLACEMENT THERAPY
Endometrial Neoplasms. *RR 8.0 for unopposed estrogen-only HRT; Tend to be less invasive than sporadically occurring ... Risk of endometrial Ca with combined estrogen-progestin HRT *Use of HRT with or without progestin was not assd with increased ... Lowers risk of endometrial cancer and hyperplasia compared with estrogen-only HRT, though may still be increased risk c/w women ... higher incidence of endometrial Ca than in the general population (RR 1.69 with 3-5y use), while continuous use was associated ...
Compound Report Card
Endometrial Neoplasms. D016889. EFO:0004230. endometrial neoplasm. 2. ClinicalTrials. Liver Diseases. D008107. EFO:0001421. ... Stomach Neoplasms. D013274. EFO:0003897. stomach neoplasm. 3. ClinicalTrials. Anus Neoplasms. D001005. EFO:0003835. anal ... Peritoneal Neoplasms. D010534. EFO:1001100. peritoneal neoplasm. 2. ClinicalTrials. Rectal Neoplasms. D012004. EFO:1000657. ... Pancreatic Neoplasms. D010190. EFO:0003860. pancreatic neoplasm. 3. ClinicalTrials. Stomach Neoplasms. D013274. EFO:0000503. ...
Compound Report Card
Endometrial Neoplasms. D016889. EFO:0004230. endometrial neoplasm. 3. ClinicalTrials. ClinicalTrials. Glioma. D005910. EFO: ... Ovarian Neoplasms. D010051. EFO:0003893. ovarian neoplasm. 3. ClinicalTrials. ClinicalTrials. Pancreatic Neoplasms. D010190. ... Nasopharyngeal Neoplasms. D009303. EFO:0004252. nasopharyngeal neoplasm. 2. ClinicalTrials. Neoplasms. D009369. EFO:0000311. ... Urethral Neoplasms. D014523. EFO:0003846. urethral neoplasm. 3. ClinicalTrials. ClinicalTrials. Uterine Cervical Neoplasms. ...
Plasma adiponectin levels and endometrial cancer risk in pre- and postmenopausal women
High circulating adiponectin levels are associated with reduced endometrial cancer risk, largely independent of other obesity- ... Plasma adiponectin levels and endometrial cancer risk in pre- and postmenopausal women J Clin Endocrinol Metab. 2007 Jan;92(1): ... Results: Adiponectin levels were inversely associated with endometrial cancer risk [body mass index-adjusted relative risk for ... Among pre- and postmenopausal women who were not currently using exogenous hormones, 284 women developed incident endometrial ...
Aspirin effects on endometrial cancer cell growth
... Obstet Gynecol. 2001 Mar;97(3):423-7. doi: 10.1016/s0029-7844(00)01161-3. ... Endometrial Neoplasms / pathology* * Female * Flow Cytometry * Humans * In Situ Nick-End Labeling ... Methods: Ishikawa human endometrial tumor cells were grown in the presence of ASA (1-5 mM) for 96 hours. Controls were treated ... Objective: To find whether aspirin (acetylsalicylic acid, ASA) inhibits the growth of endometrial cancer cells in vitro in a ...
Adjuvant radiotherapy in early stage endometrial cancer
Keywords: Genital neoplasms, female; radiotherapy, adjuvant; brachytherapy; endometrial neoplasms.. RESUMO. OBJETIVO: Comparar ... Kong A, Johnson N, Cornes P, Simera I, Collingwood M, Williams C, Kitchener H. Adjuvant radiotherapy for stage I endometrial ... Medical literature has not defined the best adjuvant treatment for stage 1A endometrial cancer, histological grades 1 and 21. ... Is there a role for a brachytherapy vaginal cuff boost in the adjuvant management of patients withuterine-confined endometrial ...
Endometrial (Uterus) Cancer | CancerIndex
... and recent research abstracts relating to endometrial cancer. Endometrial cancer is a malignancy of the endometrium (the inner ... This page has a summary of endometrial cancer, selected links to resources for patients and for health professionals, ... PubMed Central search for free-access publications about Endometrial Cancer. MeSH term: Endometrial Neoplasms. US National ... Home > Cancer Types > Gynecological > Endometrial (Uterus) Cancer Endometrial (Uterus) Cancer. Endometrial cancer is a ...
Canonical and noncanonical Wnt pathways: a comparison between endometrial cancer type I and atrophic endometrium in Brazil
Keywords : Wnt proteins; Endometrial neoplasms; Women; Postmenopause; Endometrium. · abstract in Portuguese · text in English ... MENEZES, Marina de Pádua Nogueira et al. Canonical and noncanonical Wnt pathways: a comparison between endometrial cancer type ... For this reason, we proposed to evaluate Wnt gene expression in endometrial cancer type I. DESIGN AND SETTING: Cross-sectional ... METHODS: Endometrial specimens were obtained from surgeries performed between 1995 and 2005 at São Paulo Hospital, Universidade ...
Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer
Endometrial Neoplasms. Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or ... Endometrial Stromal Tumors. Neoplasms of the endometrial stroma that sometimes involve the MYOMETRIUM. These tumors contain ... Endometrial stromal neoplasms are divided into three categories: (1) benign stromal nodules; (2) low-grade stromal sarcoma, or ... Black women with endometrial cancer are more likely to die from their disease compared to white women with endometrial cancer. ...
Body Mass and Endometrial Cancer Risk by Hormone Replacement Therapy and Cancer Subtype | Cancer Epidemiology, Biomarkers &...
endometrial neoplasm. *obesity. *body mass index. *hormone replacement therapy. Introduction. Endometrial cancer is the most ... Most incident cases of endometrial cancer were initially identified through a self-report of endometrial cancer on any of the ... Body Mass and Endometrial Cancer Risk by Hormone Replacement Therapy and Cancer Subtype. Marjorie L. McCullough, Alpa V. Patel ... Prediagnostic levels of C-peptide, IGF-I, IGFBP-1, -2 and -3 and risk of endometrial cancer. Int J Cancer 2004;108:262-8. ...
Aggressive mixed type endometrial carcinoma in a young woman with rapid progression and fatal outcome.
Nevertheless, in this report mixed type endometrial cancer including serous, clear cell and endometr ... Endometrial carcinoma in young ages is uncommon and tends to be a well differentiated endometrioid type and has an excellent ... Endometrial Neoplasms / pathology*, therapy. Fatal Outcome. Female. Humans. Menorrhagia / etiology. Mixed Tumor, Malignant / ... INTRODUCTION: Endometrial carcinoma in young ages is uncommon and tends to be a well differentiated endometrioid type and has ...
Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Recurrent, Advanced, or Metastatic Endometrial Cancer
Hormone therapy using arzoxifene hydrochloride may fight the endometrial cance ... Estrogen can stimulate the growth of endometrial cancer cells. ... Endometrial Neoplasms. *Sarcoma, Endometrial Stromal. *Adenoma ... Phase II Nonrandomized Study of LY353381-HC1 in Patients With Recurrent or Advanced Endometrial Cancer. Trial Phase:. Phase 2. ... endometrial cancer At least 12 months from time of diagnosis since prior raloxifene Prior. progesterone treatment allowed ...
The association of transforming growth factor-beta 1 with myometrial invasion of endometrial carcinomas through effects on...
... as well as myometrial invasion of endometrial cancer was studied. METHODS: The effe ... Colonic Neoplasms / chemistry, pathology. Endometrial Neoplasms / chemistry, enzymology, pathology*. Female. Gelatinases / ... Neoplasm Invasiveness*. Neoplasm Staging. Receptors, Transforming Growth Factor beta / analysis. Tissue Inhibitor of ... Plasma was obtained from 8 endometrial cancer patients with Stage-Ia disease, from 6 with Stage-Ib disease, and from 4 with ...
Delestrogen (Estradiol valerate): Side Effects, Interactions, Warning, Dosage & Uses
Malignant neoplasms. Endometrial cancer. The use of unopposed estrogens in women with intact uteri has been associated with an ... Endometrial hyperplasia may be a precursor to endometrial cancer. There are, however, possible risks that may be associated ... The reported endometrial cancer risk among unopposed estrogen users is about 2- to 12-fold greater than in non-users, and ... ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER. Close clinical surveillance of all women taking estrogens is important. ...
Ogen - FDA prescribing information, side effects and uses
2. Malignant neoplasms. a. Endometrial cancer The use of unopposed estrOgens in women with intact uteri has been associated ... See WARNINGS, Malignant neoplasms, Endometrial cancer.). CARDIOVASCULAR AND OTHER RISKS. EstrOgens with and without progestins ... Endometrial hyperplasia may be a precursor to endometrial cancer.. There are, however, possible risks that may be associated ... The reported endometrial cancer risk among unopposed estrOgen users is about 2-to-12 fold greater than in nonusers, and appears ...
Similar articles for PubMed (Select 12492084) - PubMed - NCBI
Estratest (Esterified Estrogens and Methyltestosterone): Uses, Dosage, Side Effects, Interactions, Warning
Malignant Neoplasms. Endometrial Cancer: The use of unopposed estrogens in women with intact uteri has been associated with an ... Endometrial hyperplasia may be a precursor to endometrial cancer.. There are, however, possible risks that may be associated ... See BOXED WARNINGS and WARNINGS.) For women who have a uterus, adequate diagnostic measures, such as endometrial sampling, when ... The reported endometrial cancer risk among unopposed estrogen users is about 2- to 12-fold greater than in non-users, and ...
JCM | Free Full-Text | Epithelial to Mesenchymal Transition and Cell Biology of Molecular Regulation in Endometrial...
Estrogen and progesterone signaling in EMT also play key roles in the prognosis of endometrial carcinogenesis. In this review ... leading to endometrial carcinogenesis and distant metastasis. The PI3K/AKT pathway activates the ransforming growth factor beta ... we summarize the current clinical and basic research efforts regarding the detailed molecular regulation in endometrial ... Endometrial carcinogenesis is involved in several signaling pathways and it comprises multiple steps. The four major signaling ...
Bisphenol S | GreenMedInfo | Toxic Ingredient | Natural Medicine
All About Endometrial (Uterine) Cancer | OncoLink
Uterine sarcoma is another type of endometrial (uterine) cancer. This article addresses risk, diagnosis and treatment of these ... Endometrial (uterine) cancer is the most common gynecological cancer in the US, with an estimated 55,000 new cases each year. ... of all endometrial/uterine neoplasms. There are several subtypes of uterine sarcomas, including low grade endometrial stromal ... How is endometrial cancer treated?. Surgery Almost all women with endometrial cancer will have some type of surgery during the ...
CarcinomaCancerCancersHyperplasiaEndometriumCalled endometrial cancerTumorsBiopsyMetastasisDiagnosisRecurrentHysterectomyMalignant NeoplasmsTumorUterusCases of endometrial cancerAssociated with endometrial cancerNeoplasiaCervicalEstrogenSerousVaginalUterine cancerChemotherapy2017Growth of endometrial cancer cellsRisk factors for endometrial cancerWomen diagnosed with endometrial cancerTrophoblastic NeoplasmsPatientsSubtypes of endometrial cancerTreatment of endometrial cancerMetastases of endometrial cancerSpecimensAdjuvantTumoursHigher risk for endometrialManagement of endometrial
- Here, we determined that, in contrast to other cancers, CD73 is markedly downregulated in poorly differentiated and advanced-stage endometrial carcinoma compared with levels in normal endometrium and low-grade tumors. (jci.org)
- In most cases of metastatic endometrial cancer (or metastatic endometrial carcinoma), the cancer has spread too far for it all to be removed with surgery or any other way. (diseasefix.com)
- Endometrial cancer is the most common malignancy of the female reproductive tract. (clinicaltrials.gov)
- The majority of patients with endometrial cancer are diagnosed at an early stage and cured with surgery with or without adjuvant radiotherapy. (clinicaltrials.gov)
- Because disruption of TGF-β signaling occurred independent of grade or degree of invasion and was evident in premalignant hyperplasia, we conclude that inactivation of TGF-β signaling leading to escape from normal growth control occurs at an early stage in endometrial carcinogenesis, thereby defining novel molecular targets for cancer prevention. (elsevier.com)
- Laparoscopy versus laparotomy for the management of early stage endometrial cancer. (elsevier.com)
- Traditionally, surgery for endometrial cancer (hysterectomy with removal of both fallopian tubes and ovaries) is performed through laparotomy. (elsevier.com)
- Over the last 10 to 15 years there has been a steady increase of laparoscopy for endometrial cancer. (elsevier.com)
- This review investigates the evidence of benefits and harms of laparoscopic surgery compared with laparotomy for presumed early stage endometrial cancer. (elsevier.com)
- To compare the overall survival (OS) and disease-free survival (DFS) for laparoscopic surgery versus laparotomy in women with presumed early stage endometrial cancer. (elsevier.com)
- Randomised controlled trials (RCTs) comparing laparoscopy and laparotomy for early stage endometrial cancer. (elsevier.com)
- Eight RCTs comparing laparoscopy with laparotomy for the surgical management of early stage endometrial cancer were identified.All eight trials met the inclusion criteria, 3644 women were assessed at the end of the trials. (elsevier.com)
- Three trials assessing 359 participants with early stage endometrial cancer, found no statistically significant difference in the risk of death and disease or recurrence between women who underwent laparoscopy and those who underwent laparotomy (HR = 1.14, 95% confidence interval (CI): 0.62 to 2.10) and HR = 1.13, 95% CI: 0.90 to 1.42 for OS and RFS respectively). (elsevier.com)
- This review has found evidence to support the role of laparoscopy for the management of early endometrial cancer.For presumed early stage primary endometrioid adenocarcinoma of the endometrium, laparoscopy is associated with similar overall and disease-free survival. (elsevier.com)
- Fingerprint Dive into the research topics of 'Laparoscopy versus laparotomy for the management of early stage endometrial cancer. (elsevier.com)
- Endometrial cancer is the most common gynecologic cancer in the USA and the second most common worldwide after cervical cancer. (wustl.edu)
- While common symptomatology of endometrial cancer leads to early diagnosis and favorable 5-year survival in most cases, there is a subset of cancers that have a poorer prognosis. (wustl.edu)
- The clinical and pathologic prognostic factors for endometrial cancer are well known and instrumental in determining the need for adjuvant therapy. (wustl.edu)
- Recently, research has been focused on the identification of molecular changes leading to different histologic subtypes to improve classification of endometrial cancer. (wustl.edu)
- Background: Analgesic use has been implicated in the chemoprevention of a number of solid tumors, but thus far, no previous research has focused on the role of aspirin in endometrial cancer etiology. (nebraska.edu)
- Methods: We conducted a hospital-based case-control study of 427 women with primary, incident endometrial cancer, and 427 age- and residence-matched controls without benign or malignant neoplasms. (nebraska.edu)
- Conclusion: We observed no evidence of an overall chemoprotective effect of aspirin on endometrial cancer risk, but the significant risk reductions among obese women warrant further investigation. (nebraska.edu)
- Obesity, inflammatory markers, and endometrial cancer risk: a prospective case-control study. (ox.ac.uk)
- Obesity, a major risk factor for endometrial cancer, is a low-grade inflammatory state characterized by elevated concentrations of cytokines and acute phase reactants. (ox.ac.uk)
- The current study had two aims: first to investigate the associations of C-reactive protein (CRP), interleukin 6 (IL6), and IL1 receptor antagonist (IL1Ra) with endometrial cancer risk and second to examine to which extent these markers can influence the association between obesity and endometrial cancer. (ox.ac.uk)
- We conducted a case-control study, nested within the European Prospective Investigation into Cancer and Nutrition, which comprised 305 incident cases of endometrial cancer and 574 matched controls. (ox.ac.uk)
- We observed a significant increase in risk of endometrial cancer with elevated levels of CRP (odds ratio (OR) for top versus bottom quartile: 1.58, 95% confidence interval (CI): 1.03-2.41, P(trend)=0.02), IL6 (OR for top versus bottom quartile: 1.66, 95% CI: 1.08-2.54, P(trend)=0.008), and IL1Ra (OR for top versus bottom quartile: 1.82, 95% CI: 1.22-2.73, P(trend)=0.004). (ox.ac.uk)
- The association between BMI and endometrial cancer was also substantially attenuated (∼10-20%) after adjustment for inflammatory markers, even when the effects of C-peptide or estrone had already been taken into account. (ox.ac.uk)
- We provided epidemiological evidence that chronic inflammation might mediate the association between obesity and endometrial cancer and that endometrial carcinogenesis could be promoted by an inflammatory milieu. (ox.ac.uk)
- When observed under a microscope, endometrial metastatic cancer cells have features similar to that of the primary cancer where it originated from and not like the cells of the place where the endometrial cancer has metastasized to. (diseasefix.com)
- Endometrial cancer metastasis sites: Where does endometrial cancer metastasize to generally? (diseasefix.com)
- Endometrial cancer very often metastasizes to the ovaries and fallopian tubes when the cancer is located in the upper part of the uterus, and the cervix when the cancer is in the lower part of the uterus. (diseasefix.com)
- Usually, endometrial cancer first spreads into the myometrium and the serosa, and then to other pelvic organs. (diseasefix.com)
- According to an estimate, in about 20% cases, endometrial cancer metastasizes to the lungs. (diseasefix.com)
- No other gynecologic cancer or neoplasm metastasizes this much as often. (diseasefix.com)
- How often does an endometrial cancer metastasize? (diseasefix.com)
- However, some patients have advanced primary cancer or recurrences after the primary treatment of their endometrial cancer. (diseasefix.com)
- Can stage 4 endometrial cancer be cured? (diseasefix.com)
- The management of metastatic endometrial cancer is variable, and it depends on many factors such as comorbidities, tumor grade, performance status, and past treatments etc. (diseasefix.com)
- Hormonal therapy and cytotoxic chemotherapy have been used traditionally in the treatment of metastatic endometrial cancer. (diseasefix.com)
- Multiple potential targeted therapies are also being used and evaluated for the treatment of metastatic endometrial cancer. (diseasefix.com)
- Combinations of chemotherapy drugs may be helpful in some cases of advanced metastatic endometrial cancer. (diseasefix.com)
- Women with stage IV endometrial cancer can consider taking part in clinical trials for evolving and new treatment options that are being investigated. (diseasefix.com)
- While several treatment options are now available to treat patients with metastatic endometrial cancer, the overall prognosis is still poor. (diseasefix.com)
- Endometrial cancer - Wikipedia, the free encyclopediaThis medical app for android phones will help you stay informed of the latest news, research, and publications on cancer. (gounboxing.com)
- Cancer /ˈkænsər/ ( listen), known medically as a malignant neoplasm, is a broad group of various diseases, all involving unregulated cell growth. (gounboxing.com)
- In cancer, cIf you have endometrial cancer or are close to someone who does, knowing what to expect can help you cope. (gounboxing.com)
- What is endometrial cancer? (gounboxing.com)
- Survival by stage of endometrial cancerStaging is an important phase of the diagnostic workup of cancer, it allows you to find the right treatment as well as determining a precise prognosisSurvival rates of endometrial cancer are based on outcomes of people who've had the disease. (gounboxing.com)
- Find the survival rates for endometrial cancer here. (gounboxing.com)
- Endometrial cancer - Mayo ClinicLearn about Latest cancer science discoveries, treatments, and cures. (gounboxing.com)
- The exact cause of endometrial cancer is unknown. (gounboxing.com)
- Endometrial cancer is a cancer that arises from the endometrium (the lining of the uterus or womb). (gounboxing.com)
- Topotecan is an active agent in the treatment of advanced and recurrent endometrial cancers. (clinicaltrials.gov)
- These are endometrial cancers that have spread to lymph nodes outside the pelvis or para-aortic area or to the liver, lungs, omentum, brain or other nearby or distant organs. (diseasefix.com)
- Endometrial carcinogenesis is a complex and multi-step process that features a slow progression from hyperplasia to endometrial cancer [ 1 , 2 ]. (mdpi.com)
- Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. (nih.gov)
- Estrogen receptor beta (ERbeta) in endometrial simple hyperplasia and endometrioid carcinoma. (curehunter.com)
- Safety was evaluated with peripheral blood samples for hematology, liver and renal function, and lipids, along with vital signs and interval medical evaluations.When compared with estradiol alone, combinations of drospirenone and estradiol were effective in protecting against endometrial hyperplasia. (stanford.edu)
- Just diagnosed w endometrial adenocarcenoma figo grade 1 with tubulopapillay & mucinous features, in background of endometrial hyperplasia w focal atypia. (cancer.org)
- This is called endometrial hyperplasia. (northshore.org)
- Identifying molecular markers of endometrial hyperplasia (neoplasia) progression is critical to cancer prevention. (hindawi.com)
- A neoplastic continuum from simple, to complex, to atypical hyperplasia, to endometrial carcinoma is suggested from longitudinal epidemiologic studies [ 3 - 5 ]. (hindawi.com)
- Present diagnostic capabilities utilizing histologic evaluation for endometrial hyperplasia/neoplasia alone are limited by poor diagnostic reproducibility [ 7 ] and relatively low prognostic value. (hindawi.com)
- Risk of progression to carcinoma among women with a diagnosis of endometrial hyperplasia with atypia is not well understood, though exposure to progestin therapy has been reported to be associated with an approximately 60% decreased risk of progression [ 4 , 8 ]. (hindawi.com)
- Future studies that attempt to elucidate molecular biomarkers of endometrial hyperplasia progression risk will require the development of two methodologies: the ability to perform array studies from extremely small fresh endometrial samples, as well as high-fidelity large-scale affordable array interrogation of archived FFPE samples. (hindawi.com)
- The literature refers to pyometra as the most important pathology in the feline uterus, which is often associated with cystic endometrial disease (cystic endometrial hyperplasia/pyometra complex or CEH-Pyo). (intechopen.com)
- The cystic endometrial hyperplasia-pyometra (CEH-Pyo) complex is the most frequent and important uterine disorder in queens [ 1 - 5 ]. (intechopen.com)
- Nevertheless, estrogen's effects in uterus have also been implicated as causing hyperplasia of the endometrium and cystic dilation of endometrial glands, with concomitant increased secretion of fluid that favors the progression of CEH to pyometra [ 6 , 7 ]. (intechopen.com)
- Methods: We identified 23 women with EBs performed at Mayo Clinic diagnosed as normal (n = 14) or hyperplasia (n = 9) and who later developed endometrial cancer after a median interval of 1 year. (elsevier.com)
- Cases were matched 1:1 with patients with benign EBs who did not develop EC (controls) by histology of benign EB (normal endometrium vs. endometrial hyperplasia without atypia), date of EB, age at EB, and length of post-biopsy follow-up. (elsevier.com)
- Endometrial cancer is a malignancy of the endometrium (the inner lining of the uterus, or womb) and is the most common gynaecological cancer, and accounts for 13% of all cancers in women. (cancerindex.org)
- We compared the immunohistochemical expression of Wnt1, Frizzled-1 (FZD1), Wnt5a, Frizzled-5 (FZD5) and beta-catenin between endometrial cancer type I and atrophic endometrium. (scielo.br)
- Regarding the survival curve for FZD5 in group B, we did not find any significant association between atrophic endometrium and endometrial adenocarcinoma. (scielo.br)
- The extension of endometrial tissue (ENDOMETRIUM) into the MYOMETRIUM. (bioportfolio.com)
- Most of the major known risk factors for endometrial cancer contribute to prolonged and excessive exposure of the endometrium to estrogens unopposed by progesterone, as occurs with unopposed postmenopausal estrogen therapy and obesity. (aacrjournals.org)
- Endometrial cancer develops when cells in the endometrium begin to grow out of control. (oncolink.org)
- Hysteroscopic endometrial biopsy is performed under direct visualization and is the only technique that allows for the selective biopsy of targeted areas of the endometrium. (minervamedica.it)
- But in most cases of endometrial cancer, the endometrium has built up and has not shed and thinned. (northshore.org)
- Endometrial cancer is cancer that starts in the endometrium, the lining of the uterus (womb). (medlineplus.gov)
- Here, we determined that, in contrast to other cancers, CD73 is markedly downregulated in poorly differentiated and advanced-stage endometrial carcinoma compared with levels in normal endometrium and low-grade tumors. (jci.org)
- Adenocarcinoma of the endometrium (also known as endometrial cancer or more broadly as uterine cancer or carcinoma of the uterine corpus) is the most common malignancy of the female genital tract in the United States. (jnccn.org)
- The distinction between benign and malignant tumors is very important in endometrial cancer. (oncolink.org)
- Clinicopathologic studies in endometrial carcinoma, ovarian neoplasms, and soft tissue tumors. (stanford.edu)
- To address whether the morphological differences seen in these carcinomas represent distinct characteristics at the molecular level we analyzed DNA methylation patterns in 11 papillary serous tumors, 9 endometrioid ovarian tumors, 4 normal fallopian tube samples and 6 normal endometrial tissues, plus 8 normal fallopian tube and 4 serous samples from TCGA. (gwu.edu)
- Deletions in 10q22-25 occur in multiple tumor types, most prominently advanced glial tumors (glioblastoma multiforme/anaplastic astrocytoma), but also prostate, endometrial, renal and small cell lung carcinoma, melanoma, and meningioma (see references in refs. (pnas.org)
- Although PTEN mutations are found predominantly in advanced glial and prostate tumors, mutations occur with equal frequency at all stages of endometrial cancer ( 12 ), suggesting that PTEN activation is an early event in endometrial carcinogenesis. (pnas.org)
- Pseudo-"solid pseudopapillary neoplasms" of the testis: in reality Sertoli cell tumors. (harvard.edu)
- However, molecular testing of these tumors, unlike in endometrial carcinoma, is not routinely used in clinical practice. (cancernetwork.com)
- CONCLUSIONS: The current data show a strong clustering of endometrial carcinomas and ovarian carcinomas, particularly involving tumors of endometrioid morphology. (lu.se)
- Purely mesenchymal tumors, such as those derived from smooth muscle and endometrial stroma, are considered, as are some benign and malignant neoplasms containing mixtures of epithelium and connective tissue. (springer.com)
- Frequency of known gene rearrangements in endometrial stromal tumors. (semanticscholar.org)
- Translocations resulting in gene fusion are characteristic of endometrial stromal tumors (ESTs). (semanticscholar.org)
- Chromosomal aberrations involving this gene are associated with endometrial stromal tumors. (wikipedia.org)
- Endometrial stromal sarcoma (ESS) tumors account for approximately 0.2% of all uterine malignancies [ 1 ]. (hindawi.com)
- These tumors resemble endometrial stromal cells in the proliferative stage and are often of low grade, slow growing, and indolent. (hindawi.com)
- Outpatient endometrial biopsy: the pipelle. (nextbio.com)
- The benefits of hysteroscopy in achieving a targeted endometrial biopsy under direct visualization over blind biopsy techniques are widely accepted. (minervamedica.it)
- According to the National Cancer Institute (NCI) PDQ cancer information summary for endometrial cancer screening, no evidence suggests that transvaginal sonography reduces mortality from endometrial cancer, and there is inadequate evidence that endometrial sampling (biopsy) reduces mortality. (medscape.com)
- Objective: To determine whether analysis of methylated DNA in benign endometrial biopsy (EB) specimens is associated with risk of endometrial cancer (EC). (elsevier.com)
- Objective: The aim of this study was to assess the role of frozen section (FS) in identifying an absence of lymph nodes during sentinel lymph node (SLN) biopsy for apparent early-stage endometrial cancer (EC). (elsevier.com)
- Ki67 expression in tumor cells was quantitated by immunohistochemistry with mechanical scanning within the initial endometrial biopsy and compared to that in the hysterectomy specimen for each patient in the treatment and control groups. (scirp.org)
- When "aromatase inhibitor responsiveness" was defined as proportionate decline in Ki67% stained tumor cells of at least 70% between the pre-treatment endometrial biopsy and post-treatment hysterectomy specimens, 5 of 12 patients were found to be "responsive" in the treatment group with none of the controls fulfilling these criteria. (scirp.org)
- We presented a narrative review of the current role of hysteroscopy for the diagnosis of endometrial cancer. (minervamedica.it)
- INTRODUCTION: Thanks to timely diagnosis and medical advancement the number of endometrial cancer (EC) patients achieving long term survival is constantly increasing and here comes the necessity to move forward with the understanding of post-treatment sexual adjustment and with the strategies to enhance sexual functioning (SF) and quality of life (QoL) in this population. (minervamedica.it)
- Since alpha-smooth muscle (alpha-SM) actin positive myofibroblasts characterize the desmoplastic stromal response in a variety of neoplasms , the present study was undertaken in order to establish whether these cells are also prominent in the stroma of endometrioid carcinoma and if present could be used as a valid criterion in the differential diagnosis between benign and malignant lesions. (curehunter.com)
- We discuss the epidemiology, diagnosis, and treatment of endometrial cancer on the basis of a review of observational research, randomised trials, reviews, and meta-analyses. (bmj.com)
- Diagnosis of pre cancer cells Endometrial intraepithelial neoplasm May. (cancer.org)
- Carrara L et al (2012) Could different follow-up modalities play a role in the diagnosis of asymptomatic endometrial cancer relapses? (springer.com)
- See 'Endometrial carcinoma: Clinical features and diagnosis', section on 'Clinical presentation' . (uptodate.com)
- Microscopic examination revealed multiple fragments of endometrial tissue and, report was issued with a diagnosis of combined endometrial carcinoma with a component of papillary serous endometroid and large neuroendocrine carcinoma. (alliedacademies.org)
- The study will investigate the efficacy of Sodium Cridanimod in conjunction with progestin therapy in a population of subjects with recurrent or persistent endometrial cancer, who have failed progestin monotherapy or who have been identified as PrR negative. (clinicaltrials.gov)
- The goal of this clinical research study is to learn if the combination of everolimus, letrozole, and metformin can help to control recurrent or progressive endometrial cancer. (clinicaltrials.gov)
- OBJECTIVES: I. Determine the objective tumor response rate (complete response and partial response) to arzoxifene hydrochloride in patients with recurrent or advanced endometrial cancer. (knowcancer.com)
- Determine the time to progressive disease, time to treatment failure, response duration, and survival in patients with recurrent or advanced endometrial cancer receiving arzoxifene hydrochloride. (knowcancer.com)
- MLN0128 is being evaluated as a single agent and in combination with paclitaxel or MLN1117 to treat women with advanced, recurrent, or persistent endometrial cancer. (centerwatch.com)
- Barlin JN, Puri I, Bristow RE (2010) Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis. (springer.com)
- Ponatinib in patients with recurrent or persistent endometrioid endometrial cancer (FGFR2 activating mutation positive)for tumor responses (CR + PR) Complete Response (CR): Disappearance of all target lesions. (amazonaws.com)
- Ponatinib in patients with recurrent or persistent endometrioid endometrial cancer (FGFR2 activating mutation positive) by evaluating progression-free survival Progression-free survival is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. (amazonaws.com)
- The present study of 100 endometrial samples showed focal desmoplastic stromal reaction with alpha-SM actin positive myofibroblasts in 30% of small samples and in 50% of hysterectomy specimens with endometrioid carcinoma . (curehunter.com)
- Endometrial cancer does not increase the 30-day risk of venous thromboembolism following hysterectomy compared to benign disease. (aau.dk)
- To assess RNA and DNA quantity and quality from routinely collected endometrial samples and evaluate the performance of RNA- and DNA-based arrays across endometrial tissue types, we collected fresh frozen (FF) Pipelle, FF curettage, and formalin-fixed paraffin-embedded (FFPE) hysterectomy specimens (benign indications) from eight women. (hindawi.com)
- From November 1977 to July 1987, 300 consecutive patients with endometrial carcinoma clinically confined to the uterine corpus underwent primary surgery consisting of at least abdominal hysterectomy and adnexectomy. (elsevier.com)
- Methods: In this non-randomized prospective study, 12 patients were given Femara (letrozole) 2.5 mg daily for approximately 3 weeks prior to planned hysterectomy for FIGO grade 1 or 2 endometrial carcinoma. (scirp.org)
- Although hysterectomy remains the initial treatment recommendation for most patients, women with endometrial cancer who are old and frail, or who have other serious medical conditions, experience increased risk of perioperative morbidity and mortality [3- (scirp.org)
- reported endometrial tumor shrinkage by ultrasound during brief letrozole treatment prior to hysterectomy in 10 patients with endometrial carcinoma. (scirp.org)
- A clinical trial to observe the effects of pre-hysterectomy Femara (letrozole) treatment in postmenopausal women with FIGO grade 1 or 2 endometrial carcinoma was approved by the U C Davis Human Subjects Committee. (scirp.org)
- The development of aromatase inhibitors (AIs) for the treatment of breast cancer potentially provides such a therapeutic alternative since AIs block the synthesis of estradiol, depriving the estrogen receptor of its ligand which promotes proliferation of both breast and endometrial malignant neoplasms. (scirp.org)
- mTOR inhibition with a rapamycin analogue demonstrated in vitro antiproliferative activity on endometrial AN3 CA and HEC-1-A tumor cells, and this inhibition of proliferation was found to be concentration dependent. (clinicaltrials.gov)
- The objective was to determine the effect of Caribbean nativity on outcomes in black women with endometrial cancer compared with women born in the USA, with attention paid to the effects of tumor grade, sociodemographic factors, and treatment approaches. (nih.gov)
- Ishikawa human endometrial tumor cells were grown in the presence of ASA (1-5 mM) for 96 hours. (nih.gov)
- 3 ], the factors that contribute to endometrial carcinogenesis during estrogen stimulation include polycystic ovary syndrome (PCOS), obesity, perimenopause, functional tumor, and iatrogenic events. (mdpi.com)
- Anthropometric measures and the risk of endometrial cancer, overall and by tumor microsatellite status and histological subtype. (nextbio.com)
- Here, we show that Malignant Brain Tumor Domain-containing Protein 1 (MBTD1), a member of the polycomb group protein family, is critical for human endometrial stromal cell (HESC) decidualization. (frontiersin.org)
- The tumor showed the characteristic morphology of a low-grade spindle neoplasm with uniform proliferation of small round to oval cells, minimal nuclear atypia or mitoses, and small nucleoli (Figure 1 ). (hindawi.com)
- The association of tumor and patient characteristics with an EN was evaluated, and trend analysis to compare the rate of ENs over calendar quarters was performed. (elsevier.com)
- Objective: To determine if short-term treatment with Femara (letrozole) induces measurable reduction in tumor Ki67 expression in postmenopausal women with FIGO grade 1 and 2 endometrial carcinoma. (scirp.org)
- Conclusion: Femara (letrozole) 2.5 mg daily for approximately 3 weeks induced a significant reduction in tumor cell Ki67 expression among 5 of 12 (41%) postmenopausal women with FIGO grade 1 or 2 endometrial carcinoma. (scirp.org)
- Here we report the results of a pilot clinical trial asking if short-term AI treatment of FIGO grade 1 or 2 endometrial carcinoma in postmenopausal women is associated with significant decline in tumor Ki67 expression. (scirp.org)
- It usually occurs in women in their reproductive years and may result in a diffusely enlarged uterus with ectopic and benign endometrial glands and stroma. (bioportfolio.com)
- When estrogen is prescribed for a postmenopausal woman with a uterus , progestin should also be initiated to reduce the risk of endometrial cancer . (rxlist.com)
- There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. (nih.gov)
- Endometrial cancer is also called cancer of the uterus, or uterine cancer. (northshore.org)
- The main treatment for endometrial cancer is surgery to remove the uterus plus the cervix, ovaries, and fallopian tubes. (northshore.org)
- If endometrial cancer isn't treated, it may spread outside of the uterus. (northshore.org)
- This chapter deals with neoplasms of the uterus in which there is mesenchymal differentiation. (springer.com)
- The categories used here are slightly modified from the comprehensive classification of mesenchymal neoplasms of the uterus developed by the World Health Organization (WHO) (Kurman et al. (springer.com)
Cases of endometrial cancer2
Associated with endometrial cancer1
- Though endometrial carcinoma is the most common gynecologic malignant neoplasm [ 1 ], diagnostic capabilities and management of endometrial precancer (intraepithelial neoplasia) lag far behind those of cervical carcinoma [ 2 ]. (hindawi.com)
- Identification of molecular alterations present in various stages of endometrial neoplasia will provide the basis for early detection and therapeutics [ 6 ]. (hindawi.com)
- Tissue archives of longitudinal endometrial neoplasia (intraepithelial neoplasm) specimens represent a potentially valuable resource for genomic studies, but they are typically comprised of formalin-fixed paraffin-embedded (FFPE) samples [ 4 , 5 ]. (hindawi.com)
- PURPOSE: This randomized phase III trial is studying two different methods of radiation and their side effects and comparing how well they work in treating endometrial and cervical cancer after surgery. (clinicaltrials.gov)
- To validate EPIC bowel and urinary domains in women undergoing either IMRT pelvic radiation treatment or four-field pelvic radiation treatment for endometrial or cervical cancer. (clinicaltrials.gov)
- Patients are stratified according to type of cancer (endometrial vs cervical), chemotherapy (none vs 5 courses of weekly cisplatin at 40 mg/m²), and radiation dose (45 Gy vs 50.4 Gy). (clinicaltrials.gov)
- Estrogen and progesterone signaling in EMT also play key roles in the prognosis of endometrial carcinogenesis. (mdpi.com)
- There is no evidence that the use of 'natural' estrogens results in a different endometrial risk profile than synthetic estrogens at equivalent estrogen doses. (rxlist.com)
- Additionally, the NCI's PDQ cancer information summary and ACS agree that for women at increased risk for endometrial cancer due to a history of receiving either estrogen therapy or tamoxifen therapy, there is no indication that routine screening would improve early detection or survival rates. (medscape.com)
- The NCI's PDQ cancer information summary notes that the use of oral contraceptives containing estrogen and progesterone for at least 1 year reduces the risk for developing endometrial cancer. (medscape.com)
- When progesterone concentration increases, estrogen action is inhibited in uterine epithelia, and endometrial stromal cell decidualization initiates. (frontiersin.org)
- The most common cause of type I endometrial cancer is having too much of the hormone estrogen compared to the hormone progesterone in the body. (northshore.org)
- Both neoplasms are associated with obesity, nulliparity, and use of exogenous estrogen and tamoxifen [ 9-17 ]. (uptodate.com)
- Nevertheless, in this report mixed type endometrial cancer including serous, clear cell and endometrioid components in a young patient with rapid progression and fatal outcome is presented. (biomedsearch.com)
- I was referred to a University hospital who changed my pathologt report to serous endometrial carciinoma in a polyp. (cancer.org)
- Abushahin N, Zhang T, Chiang S, Zhang X, Hatch K, Zheng W (2011) Serous endometrial intraepithelial carcinoma arising in adenomyosis: a report of 5 cases. (springer.com)
- The patient did not permit any vaginal intervention including endometrial sampling, therefore laparotomy was decided. (biomedsearch.com)
- Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal vaginal bleeding. (rxlist.com)
- Bristow RE et al (2006) Cost-effectiveness of routine vaginal cytology for endometrial cancer surveillance. (springer.com)
- Unexpected vaginal bleeding after menopause is the most common symptom of endometrial cancer. (northshore.org)
- Before menopause, abnormal bleeding or vaginal discharge is not as likely to be a sign of endometrial cancer. (northshore.org)
- Of women who have endometrial cancer after menopause, most have vaginal bleeding. (northshore.org)
- This topic focuses on type I endometrial cancer, which is the most common kind of uterine cancer. (northshore.org)
- Register the Administrator's establishing the WTC Health Program site uterine cancer, including its determination not to publish such a within the Department of Health and subtype, endometrial cancer, to the List. (cdc.gov)
Growth of endometrial cancer cells2
- It is designed to lower insulin levels, which may slow or stop the growth of endometrial cancer cells. (clinicaltrials.gov)
- To find whether aspirin (acetylsalicylic acid, ASA) inhibits the growth of endometrial cancer cells in vitro in a way similar to that in colorectal cancer cells and to investigate the mechanisms by which aspirin might lead to growth inhibition. (nih.gov)
Risk factors for endometrial cancer1
Women diagnosed with endometrial cancer2
- The majority of women diagnosed with endometrial cancer have already gone through menopause, although it can occur in younger women as well. (oncolink.org)
- In addition, Lynch syndrome genetic testing should be done for all women diagnosed with endometrial cancer before age 50 and family members of anyone with Lynch syndrome. (medscape.com)
- All patients must have endometrial cancer PrR status determined from an archival sample at Screening. (clinicaltrials.gov)
- The majority of patients with endometrial cancer are diagnosed at an early stage and cured with surgery with or without adjuvant radiotherapy. (clinicaltrials.gov)
- Follow-up of Endometrial Cancer Patients: A Valuable Medical Intervention or a Dispensable Force of Habit? (knowcancer.com)
- Plasma was obtained from 8 endometrial cancer patients with Stage-Ia disease, from 6 with Stage-Ib disease, and from 4 with Stage-Ic disease, and the levels of TGF-beta 1 were measured by enzyme immunoassays. (biomedsearch.com)
- In April 2018 the first German interdisciplinary S3 guideline for the diagnostics, treatment, and follow-up of patients with endometrial cancer was published. (springer.com)
- Creutzberg CL et al (2003) Survival after relapse in patients with endometrial cancer: results from a randomized trial. (springer.com)
- Gadducci A et al (2000) An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer. (springer.com)
- We postulate that Ki67 may be a useful marker during aromatase inhibitor medical treatment of patients with endometrial cancer who are not candidates for surgical treatment. (scirp.org)
- We reasoned that Ki67 expression may also be a useful marker to help with the monitoring and management of patients with endometrial cancer who are being given AI medical treatment. (scirp.org)
Subtypes of endometrial cancer2
Treatment of endometrial cancer1
Metastases of endometrial cancer1
- Surgery is the primary treatment for stage 1 endometrial cancer, and radiotherapy can be used as adjuvant treatment. (scielo.br)
- Medical literature has not defined the best adjuvant treatment for stage 1A endometrial cancer, histological grades 1 and 2 1 . (scielo.br)
- Receipt of adjuvant endometrial cancer treatment according to race: An NRG Oncology/Gynecologic Oncology Group 210 Study. (bioportfolio.com)
- Neuroendocrine Tumours (NEC), are neoplasms that arise from cells of the endocrine (hormonal) and nervous systems. (alliedacademies.org)
- Type I neoplasms are now generally referred to as endometrial stromal tumours with sex cord‐like elements while type II tumours are designated UTROSCT. (pubmedcentralcanada.ca)
- 2 In the latest World Health Organization classification of tumours of the female genital organs, UTROSCT is classified separately to endometrial stromal neoplasms. (pubmedcentralcanada.ca)
- 2 However, there is ongoing debate as to the exact histogenesis, ie whether they represent variants of endometrial stromal neoplasm or are separate unrelated tumours. (pubmedcentralcanada.ca)